Migraine

Complex MONDO:0005277 Pathograph 14 Show in embeddings browser Neurological Disease

Migraine is a common chronic neurological disorder characterized by recurrent attacks of moderate-to-severe, often unilateral pulsating headache accompanied by nausea, photophobia, and phonophobia, occurring with or without aura. Its pathophysiology involves cortical spreading depression (the substrate of aura), activation and sensitization of the trigeminovascular system, and release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP).

Ask OpenScientist

Ask a research question about Migraine. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

9
Pathophys.
7
Phenotypes
2
Hypotheses
2
Gaps
14
Pathograph
5
Genes
11
Medical Actions
4
Subtypes
4
Datasets
3
Trials
11
References
2
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
◆

Subtypes

4
Migraine with Aura
Preceded by transient neurological symptoms (visual, sensory, speech).
Show evidence (2 references)
PMID:1525797 SUPPORT
"Lifetime prevalence of MA was 5%, male:female ratio 1:2."
Population study establishes migraine with aura as a distinct subtype with 5% lifetime prevalence.
PMID:1525797 SUPPORT
"Visual disturbances were the most common aura phenomenon occurring in 90% of subjects with MA."
Visual symptoms are the predominant aura type, occurring in 90% of migraine with aura cases.
Migraine without Aura
Most common form, no preceding aura.
Show evidence (2 references)
PMID:1525797 SUPPORT
"Lifetime prevalence of MO was 8%, M:F ratio 1:7."
Migraine without aura is the most common form with 8% lifetime prevalence and strong female predominance.
PMID:1525797 SUPPORT
"Women, but not men, were significantly more likely to have MO than MA."
Migraine without aura shows stronger female predominance than migraine with aura.
Chronic Migraine
Headache on 15 or more days per month for more than 3 months, of which at least 8 days have migraine features - the ICHD-3 diagnostic threshold that separates chronic from episodic migraine.
Show evidence (1 reference)
PMID:30893319 SUPPORT Human Clinical
"For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0-4.3)."
Analysed separately from episodic migraine in this meta-analysis, supporting chronic migraine as a distinct treatment population; the snippet does not state the diagnostic day-count criterion.
Vestibular Migraine
Migraine with prominent vestibular symptoms (vertigo, dizziness) occurring with or without headache. Characterized by recurrent episodes of moderate to severe vestibular symptoms (spontaneous, positional, visually-induced, or head-motion-induced vertigo/dizziness) lasting 5 minutes to 72 hours, with migraine-associated features such as photophobia, phonophobia, and nausea. Underlies abnormal central integration of vestibular, visual, and nociceptive inputs due to trigemino-vestibular pathway dysfunction. Central dysfunction is the primary mechanism but not the only one: peripheral vestibular abnormalities on vHIT or caloric testing are present in a subset of patients, so the source concludes vestibular migraine should not be read as a purely central disorder in every case.
Show evidence (5 references)
PMID:38619053 SUPPORT
"Vestibular migraine is an underdiagnosed migraine phenotype that shares the pathophysiological mechanisms of migraine, with growing interest in recent years."
Vestibular migraine is established as a distinct underdiagnosed migraine phenotype.
PMID:42643076 SUPPORT Other
"Vestibular migraine should be approached as a multisystem neurovestibular disorder rather than a simple coexistence of migraine and vertigo."
The review's own recommendation, quoted as the source sentence behind this subtype's multisystem framing. Graded OTHER rather than HUMAN_CLINICAL because the quoted text is the authors' synthesis and recommendation over the literature, not an observation in a patient cohort.
PMID:42643076 SUPPORT Human Clinical
"Current evidence supports vestibular migraine as a complex disorder involving trigeminovascular activation, CGRP signaling, central sensitization, vestibulo-thalamo-cortical networks, and cerebellar compensation."
Systematic review of 72 studies affirms the multisystem neurovestibular nature of vestibular migraine, involving trigemino-vestibular interactions and central network dysfunction beyond simple coexistence of migraine and vertigo.
+ 2 more references
C

Comorbidities

Achoo Syndrome <-> Migraine
Disease B UNKNOWN CURATED
Hypermobile Ehlers-Danlos Syndrome <-> Migraine
Disease B UNKNOWN CANDIDATE
◈

Mechanistic Hypotheses

2
CSD-Initiated Migraine (Aura Pathway)
csd_initiated_migraine CANONICAL
Evidence balance 2 support
In migraine with aura, cortical spreading depression (CSD) — a slowly propagating wave of neuronal and glial depolarization — initiates the aura phase and drives downstream trigeminovascular activation. CSD releases inflammatory mediators (HMGB1, ATP, prostaglandins) via pannexin-1 channels, which sensitize meningeal trigeminal afferents, trigger CGRP release from peripheral and central trigeminal terminals, and culminate in the headache phase. The premonitory hypothalamic/brainstem network may lower the CSD threshold. This pathway is well established in animal models and supported by the efficacy of CGRP-targeting therapies in both aura and non-aura forms.
Pathograph links
Cortical Spreading Depression -> Trigeminovascular Activation DIRECT CSD releases inflammatory mediators (HMGB1, prostaglandins) via pannexin-1 channels and activates meningeal trigeminal nociceptors, driving the trigeminovascular activation that initiates the headache phase.
Show evidence (2 references)
PMID:37495957 SUPPORT Model Organism
"Cortical spreading depolarization (CSD), the neurophysiological correlate of the migraine aura, can activate trigeminal pain pathways, but the neurobiological mechanisms and behavioural consequences remain unclear."
Establishes CSD as the neurophysiological basis of migraine aura and its downstream role in activating trigeminal pain pathways, supporting the CSD-initiated migraine hypothesis.
PMID:29697154 SUPPORT Human Clinical
"In one-third of patients, an aura phase may occur during some attacks and likely correlates with a cortical spreading depression-like event; a slowly propagating wave of neuronal and glial cell depolarization and hyperpolarization."
Phase-by-phase review establishes CSD as the mechanistic basis of aura in one-third of migraine attacks, supporting the CSD-initiated pathway.
Brainstem/Hypothalamic-Initiated Migraine (Non-Aura Pathway)
brainstem_hypothalamic_migraine EMERGING
Evidence balance 1 support
In migraine without aura — the most common form — headache initiates without evident CSD. Instead, premonitory activation of hypothalamic and brainstem circuits (locus coeruleus, dorsal raphe, periaqueductal gray) modulates trigeminal nucleus caudalis excitability, lowering the threshold for trigeminovascular activation. The hypothalamic premonitory network directly sensitizes the trigeminovascular pathway via descending modulation, leading to CGRP release and headache without a cortical CSD step. This pathway explains the premonitory symptoms (fatigue, yawning, food cravings) that precede headache onset by up to 72 hours.
Show evidence (1 reference)
PMID:29697154 SUPPORT Human Clinical
"The premonitory phase begins as early as 3 days before the headache phase, and involves a complex interplay between various cortical and subcortical brain regions, including the hypothalamus and brainstem nuclei that modulate nociceptive signaling. The headache phase involves activation of the..."
Establishes that the premonitory hypothalamic/brainstem network drives trigeminovascular activation in migraine, supporting an initiation pathway that operates independent of overt CSD.
?

Discussions and Knowledge Gaps

2
What molecular and circuit-level mechanisms drive the transition from episodic migraine (fewer than 15 headache days/month) to chronic migraine (15 or more days/month), and does the CGRP-driven shift from activity-dependent to activity-independent central sensitization account for chronification?
KNOWLEDGE GAP OPEN gap_migraine_episodic_to_chronic_chronification
Attached to
pathophysiology#Central Sensitization pathophysiology#CGRP Pathway
PMID:30982963 proposes that a shift in central sensitization from activity-dependent (triggered only during attacks) to activity-independent (present interictally) may be the key mechanism of chronification. However, the upstream triggers of this shift — cumulative microglial sensitization, medication overuse, repeated CSD episodes, or genetic predisposition — remain unclear. Understanding this transition is clinically critical because it defines who progresses from episodic to chronic migraine and informs preventive treatment selection.
In migraine without aura, does premonitory hypothalamic/brainstem activation directly gate the trigeminovascular pathway without cortical spreading depression, and which neuroimaging markers can distinguish this brainstem-initiated pathway from the CSD-initiated aura pathway?
KNOWLEDGE GAP OPEN gap_migraine_mwoa_premonitory_initiation
Attached to
pathophysiology#Cortical Spreading Depression pathophysiology#Trigeminovascular Activation
The mechanistic_hypotheses block encodes two initiation routes for migraine: CSD-initiated (canonical for MwA) and brainstem/hypothalamic-initiated (emerging model for MwoA). The brainstem-initiation route is supported by premonitory symptom timing and functional MRI studies showing hypothalamic activation before headache onset, but direct causal evidence that hypothalamic circuits gate trigeminovascular activation independent of CSD is lacking. Differentiating these pathways has implications for subtype-specific preventive therapies.
⚙

Pathophysiology

9
Cortical Spreading Depression
Wave of neuronal depolarization spreading across cortex underlies aura. Triggers activation of trigeminal pathways and may initiate headache phase.
CSD-Initiated Migraine (Aura Pathway)
Neural Signaling GO:0007268 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Neural Signaling, annotated with chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology.
Downstream
Trigeminovascular Activation CSD releases inflammatory mediators (HMGB1, prostaglandins) via pannexin-1 channels and activates meningeal trigeminal nociceptors, driving the trigeminovascular activation that initiates the headache phase. CSD-Initiated Migraine (Aura Pathway)
Show evidence (4 references)
PMID:37495957 SUPPORT
"Cortical spreading depolarization (CSD), the neurophysiological correlate of the migraine aura, can activate trigeminal pain pathways, but the neurobiological mechanisms and behavioural consequences remain unclear."
Establishes CSD as the neurophysiological basis of migraine aura and its role in activating trigeminal pain pathways.
PMID:37495957 SUPPORT Model Organism
"In both WT and FHM1 mutant mice, CSDs induced headache-related behaviour, as evidenced by increased MGS scores and the occurrence of oculotemporal strokes, at 30 min."
Demonstrates that CSDs directly induce headache-related behaviors in animal models, supporting CSD's role in headache initiation.
PMID:37495957 SUPPORT Model Organism
"Blocking Panx1 channels by TAT-Panx308 inhibited CSD-induced headache related behaviour and HMGB1 release."
Shows that pannexin-1 channels mediate CSD-induced neuroinflammatory signaling and headache behaviors, identifying a key mechanism linking CSD to pain.
+ 1 more reference
Trigeminovascular Activation
Activation of trigeminal nerve fibers innervating meningeal blood vessels releases CGRP and other neuropeptides, causing neurogenic inflammation and pain.
TRPM3 hgnc:17992 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TRPM3 (hgnc:17992). hgnc:17992 is a gene from the HUGO Gene Nomenclature Committee.
Pain Signaling GO:0048265 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Pain Signaling, annotated with response to pain (GO:0048265). GO:0048265 is a biological process from the Gene Ontology.
Downstream
PACAP Pathway Activated trigeminal afferents release PACAP alongside CGRP, so trigeminovascular activation feeds the PACAP arm as well as the CGRP one.
CGRP Pathway Activated trigeminal afferents release CGRP from peripheral nerve and central nerve terminals, initiating vasodilation and neurogenic inflammation in the meninges.
Trigemino-Vestibular Pathway Trigeminovascular activation during an attack reaches structures anatomically and functionally linked to the vestibular system, not only the pain pathways, which is the upstream entry point for the vestibular arm of this entry.
Show evidence (5 references)
PMID:37487740 SUPPORT
"CSD is also thought to drive the headache phase in migraine by promoting the activation and mechanical sensitization of trigeminal primary afferent nociceptive neurons that innervate the cranial meninges."
Confirms that CSD drives trigeminovascular activation leading to headache phase in migraine.
PMID:39080518 SUPPORT Model Organism
"Studies in rodents have demonstrated that sterile meningeal inflammation can stimulate and sensitize meningeal nociceptors, culminating in headaches."
Shows that meningeal inflammation activates and sensitizes trigeminal nociceptors, producing headache.
PMID:39080518 SUPPORT
"The parenchymal neuroinflammatory signaling involving neurons, astrocytes, and microglia, which eventually extends to the meninges, can link non-homeostatic perturbations in the insensate brain to pain-sensitive meninges."
Describes the pathway by which brain parenchymal inflammation extends to activate pain-sensitive meningeal structures and trigeminal afferents.
+ 2 more references
Central Sensitization
Repeated activation leads to sensitization of trigeminal nucleus and thalamic neurons, producing allodynia and enhanced pain perception.
Show evidence (3 references)
PMID:30982963 SUPPORT Other
"progresses from peripheral sensitization of the primary afferent TG neurons to central sensitization of TNC second-order neurons and ultimately to central sensitization of third-order neurons in the thalamus."
Directly states the node's claim - sensitization of trigeminal nucleus caudalis second-order neurons and of thalamic third-order neurons, which is what distinguishes central from peripheral sensitization.
PMID:30982963 SUPPORT Human Clinical
"As the migraine attack progresses, cutaneous allodynia develops in the periorbital area, signaling central sensitization of convergent TNC neurons and an increased resistance to the efficacy of triptans."
Links the allodynia asserted by this node to central sensitization of convergent TNC neurons in patients during attacks.
PMID:37487740 SUPPORT Model Organism
"Broad-spectrum P2X receptor inhibition, selective blockade of the P2X7 receptor, and its related Pannexin 1 channel suppressed CSD-evoked afferent mechanical sensitization but did not affect the accompanying afferent activation response."
Support is PARTIAL because this addresses mechanical sensitization of meningeal primary afferents - the peripheral limb that feeds central sensitization - not sensitization of the second- and third-order CNS neurons this node describes.
CGRP Pathway
Calcitonin gene-related peptide (CGRP) release from trigeminal neurons causes vasodilation and neurogenic inflammation. CGRP blockers are effective treatments.
Downstream
Central Sensitization Peripheral CGRP release perpetuates trigeminal nerve sensitization and drives central sensitization of second-order neurons in the trigeminal nucleus caudalis and thalamus, producing allodynia and enhanced pain perception.
Vestibular CGRP Signaling CGRP released during the attack acts on trigeminal terminals innervating inner ear structures and on CGRP receptors in the vestibular nuclei, so the same peptide that drives the pain arm also drives the vestibular one.
Show evidence (4 references)
PMID:39080518 SUPPORT
"The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."
Clinical efficacy of CGRP-targeting therapies validates the central role of the CGRP pathway in migraine pathophysiology.
PMID:37569648 SUPPORT
"However, the progresses in unravelling the migraine pathophysiology allowed identifying novel putative targets as calcitonin gene-related peptide (CGRP)."
Identifies CGRP as a key validated target in migraine treatment based on understanding of disease pathophysiology.
PMID:37569648 SUPPORT
"Nevertheless, despite the revolution brought by CGRP monoclonal antibodies and gepants, a significant percentage of patients still remains burdened by an unsatisfactory response, suggesting that other pathways may play a critical role"
Notes that while CGRP pathway is important, treatment resistance in some patients indicates involvement of additional pathways beyond CGRP.
+ 1 more reference
Trigemino-Vestibular Pathway
Glutamatergic projections from the caudal trigeminal nucleus directly innervate vestibular nuclei. During migraine attacks, trigeminal nociceptive activation and CGRP release from trigeminal terminals drive vestibular nucleus sensitization, generating central vestibular hypersensitivity. This pathway is the mechanistic bridge linking migraine biology to vestibular symptoms in vestibular migraine.
Nociceptive Signaling GO:0048265 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Nociceptive Signaling, annotated with response to pain (GO:0048265). GO:0048265 is a biological process from the Gene Ontology. Glutamatergic Synaptic Transmission GO:0035249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Glutamatergic Synaptic Transmission, annotated with synaptic transmission, glutamatergic (GO:0035249). GO:0035249 is a biological process from the Gene Ontology.
Downstream
Vestibulo-Thalamo-Cortical Dysfunction Sensitized vestibular nuclei drive abnormal activity and altered multisensory integration in the vestibulo-thalamo-cortical networks, causing impaired balance between vestibular, visual, and auditory inputs. This produces motion intolerance, visual motion sensitivity, and vertigo.
Show evidence (3 references)
PMID:42643076 SUPPORT Model Organism
"The trigemino-vestibular projection is glutamatergic, originates in the caudal trigeminal nucleus, and projects to the vestibular nuclei, where it mediates vestibular dysfunction in chronic nitroglycerin migraine models; silencing this projection reduces vestibular dysfunction."
Mechanistic evidence from chronic migraine animal models demonstrates that glutamatergic trigemino-vestibular projections drive vestibular nucleus sensitization and that blocking them rescues vestibular dysfunction.
PMID:42643076 SUPPORT Model Organism
"Trigeminal nociceptive pathways interact with vestibular nuclei, which generate central sensitivity during attacks. Experimental models demonstrate both glutamatergic projections from the caudal trigeminal nucleus to the vestibular nuclei and increased neuronal activation in vestibular centers..."
Shows that trigeminal-vestibular interactions produce central vestibular sensitization, with increased neuronal activation in vestibular nuclei during migraine-like activation.
PMID:42643076 SUPPORT Model Organism
"Following chronic migraine paradigms, abnormal synaptic protein expression and altered synaptic morphology have been reported in the vestibular nucleus, consistent with central sensitization processes."
Demonstrates that chronic migraine triggers synaptic plasticity changes in the vestibular nucleus, supporting a central sensitization mechanism in vestibular migraine.
Vestibulo-Thalamo-Cortical Dysfunction
Abnormal modulation within multimodal cortical networks (temporo-parieto-insular vestibular cortex, thalamus, visual cortex) due to sensitized vestibular/trigeminal input. Impaired reciprocal inhibition between visual and vestibular systems causes visual motion sensitivity and vertigo. Central sensitization of thalamocortical networks produces widespread sensory hypersensitivity (allodynia, tinnitus, visual/auditory oversensitivity).
Multisensory Integration Relation: this pathophysiological event involves this biological process This pathophysiological event involves Multisensory Integration.
Downstream
Vertigo Abnormal vestibulo-thalamo-cortical integration produces vestibular symptoms (spontaneous, positional, visually-induced, or head-motion-induced vertigo/dizziness) that may occur with or without headache during vestibular migraine attacks.
Show evidence (2 references)
PMID:42643076 SUPPORT Human Clinical
"The disruption of reciprocal inhibition between the visual and vestibular systems may explain visual motion sensitivity and vertigo-like visual symptoms."
Imaging evidence shows that vestibular migraine attacks involve disrupted visual-vestibular balance, explaining visual motion sensitivity and vertigo.
PMID:42643076 SUPPORT Human Clinical
"Central sensitization is an increasingly important mechanism in VM. Phenotypes associated with widespread cutaneous allodynia, sleep disturbances, tinnitus, depressive symptoms, and high disability can be interpreted as clinical manifestations of increased sensitivity in thalamocortical sensory..."
Establishes that vestibular migraine phenotypes with widespread multisensory hypersensitivity (allodynia, tinnitus, auditory/visual oversensitivity) reflect central sensitization in thalamocortical networks.
Vestibulo-Cerebellar Integration Failure and Compensation
The vestibulocerebellum and deep cerebellar nuclei are among the sites where vestibular and trigeminal nociceptive signals converge, and they carry the canal-otolith integration that builds a stable percept of head orientation. Defective central synthesis of cerebellar origin is inferred from raised thresholds and delayed tilt perception under combined canal-otolith stimulation. The same networks are the substrate for recovery: cerebellar functional activity changes after vestibular rehabilitation, which is why this node carries both the deficit and the compensation it permits. This is the fifth of the five mechanism families the source's own summary names, and it is the one that makes vestibular rehabilitation mechanistically intelligible rather than merely empirical.
vestibulocerebellum UBERON:0014642 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vestibulocerebellum (UBERON:0014642). UBERON:0014642 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Vertigo Failure of cerebellar canal-otolith synthesis contributes to the vestibular symptoms of an attack through the same convergence sites at which trigeminal and vestibular signals interact. Reversibility of this arm is what vestibular rehabilitation is thought to exploit.
Show evidence (3 references)
PMID:42643076 SUPPORT Human Clinical
"The brainstem and cerebellar nuclei, vestibular nuclei, and vestibulocerebellum have repeatedly been identified as sites where vestibular and nociceptive (trigeminal) signals interact; this interaction may trigger vestibular symptoms in migraine episodes"
Establishes the cerebellar nuclei and vestibulocerebellum as convergence sites for vestibular and trigeminal nociceptive signals, which is the anatomical claim this node rests on.
PMID:42643076 SUPPORT INDIRECT Human Clinical
"Patients with abnormal integration exhibit reduced motion detection thresholds and delayed formation of tilt perceptions during combined canal-otolith stimulation; this likely implies central synthesis defects of cerebellar"
The psychophysical measurement behind the deficit half of this node. Graded INDIRECT because the cerebellar localization is the source's own inference from the perceptual thresholds ("likely implies"), not a direct observation of cerebellar function.
PMID:42643076 SUPPORT Human Clinical
"The role of cerebellar and vestibulo-cerebellar networks is also significant."
The source's own statement that these networks are a substantive part of vestibular migraine pathophysiology, supporting curation of this node at all rather than folding it into the thalamo-cortical node above.
Vestibular CGRP Signaling
CGRP is expressed in trigeminal terminals innervating the inner ear, vestibular nuclei, and vestibulo-cerebellar networks. CGRP release during migraine attacks increases excitability and sensitivity in central vestibular pathways (via PKC/ERK/CREB activation) and modulates peripheral inner ear electrophysiology. This dual-level CGRP signaling (peripheral and central) is the mechanistic basis for CGRP-targeted therapy efficacy in vestibular migraine.
Vestibular CGRP receptor signaling GO:1990408 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Vestibular CGRP receptor signaling, annotated with calcitonin gene-related peptide receptor signaling pathway (GO:1990408). GO:1990408 is a biological process from the Gene Ontology.
Downstream
Trigemino-Vestibular Pathway CGRP released from activated trigeminal terminals drives sensitization of vestibular nuclei through peripheral and central mechanisms, amplifying trigemino-vestibular interactions and central vestibular dysfunction.
Show evidence (4 references)
PMID:42643076 SUPPORT Human Clinical
"Trigeminal innervation and CGRP expression in inner ear structures are interpreted as a biological bridge between migraine biology and otologic/vestibular symptoms."
Establishes CGRP as the biological bridge linking trigeminovascular activation to vestibular symptoms through CGRP expression in trigeminal terminals and inner ear structures.
PMID:42643076 SUPPORT Model Organism
"Following repeated migraine triggers, CGRP levels and CGRP receptor components (calcitonin receptor-like receptor and receptor activity-modifying protein 1) are upregulated in the vestibular nuclei, and in animal models, local CGRP inhibition or CGRP receptor antagonism reduces c-fos activation..."
Shows that chronic migraine upregulates CGRP signaling in vestibular nuclei and that blocking CGRP reduces vestibular nucleus activation and behavioral vestibular dysfunction.
PMID:42643076 SUPPORT Model Organism
"CGRP1 receptor activity in the vestibular nucleus activates the PKC/ERK/CREB pathways and alters synaptic transmission"
Delineates the intracellular cascade (PKC/ERK/CREB) downstream of vestibular CGRP1 receptor activation as a mechanism of central sensitization in vestibular migraine.
+ 1 more reference
PACAP Pathway
Pituitary adenylate cyclase-activating peptide (PACAP) is expressed in migraine-related regions including the hypothalamus, pons, thalamus, trigeminal ganglia and trigeminal nucleus caudalis, and operates at least partly in parallel to CGRP in trigeminovascular nociceptive signaling. PACAP infusion provokes migraine attacks in susceptible individuals, and the pathway is a target for preventive therapy.
neuropeptide signaling pathway GO:0007218 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves neuropeptide signaling pathway (GO:0007218). GO:0007218 is a biological process from the Gene Ontology.
Downstream
Central Sensitization PACAP released during the headache phase contributes to nociceptive transmission within the trigeminovascular system, alongside CGRP, and so feeds the sensitization that maintains the attack.
Show evidence (3 references)
PMID:42676555 SUPPORT REVIEW SYNTHESIS Other
"Pituitary adenylate cyclase-activating polypeptide (PACAP) is another important neuropeptide within the trigeminovascular network and, like CGRP, can provoke migraine in susceptible individuals"
PACAP provokes migraine attacks in humans, establishing it as a major effector neuropeptide alongside CGRP in migraine pathophysiology.
PMID:42676555 SUPPORT REVIEW SYNTHESIS Other
"Mechanistically, PACAP is highly relevant to migraine biology because it is expressed in migraine‐related regions including the hypothalamus, pons, thalamus, trigeminal ganglia, and trigeminal nucleus caudalis, and PACAP infusion can provoke migraine attacks in susceptible individuals"
Sources the expression distribution recorded in this node's description, which is an expression statement rather than a claim about release from trigeminal neurons specifically.
DOI:10.1186/s10194-024-01830-2 SUPPORT PRIMARY RESULT Model Organism
"This study assessed all three PACAP receptors in a migraine mouse model and suggests a significant role of VPAC receptors in migraine pathophysiology."
Receptor-level resolution of the pathway: knockout work in a migraine mouse model attributes PACAP38-induced hypersensitivity and carotid dilatation to VPAC1/VPAC2 rather than to PAC1, which is the mechanistic reason ligand-directed therapy outperformed PAC1 blockade.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Migraine Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Digestive 1
Nausea VERY_FREQUENT HP:0002018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nausea (HP:0002018). HP:0002018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30982963 SUPPORT Human Clinical
"may be accompanied by associated symptoms of photophobia, phonophobia, osmophobia, allodynia, pain on movement, and nausea and vomiting."
Nausea and vomiting are established associated symptoms of the migraine headache phase.
Ear 1
Vertigo OCCASIONAL HP:0002321 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vertigo (HP:0002321). HP:0002321 is a phenotype from the Human Phenotype Ontology.
Vestibular migraine - spontaneous, positional, visually-induced, or head-motion-induced
Show evidence (5 references)
PMID:38619053 SUPPORT
"Vestibular migraine is an underdiagnosed migraine phenotype that shares the pathophysiological mechanisms of migraine, with growing interest in recent years."
Establishes vestibular migraine as a recognized migraine phenotype where vertigo is a prominent symptom.
PMID:37889468 SUPPORT
"There is evidence of abnormal sensory processing and integration in VM patients. Calcitonin gene-related peptide (CGRP) has also been found to play a role in trigeminal and vestibular nucleus pathways."
Links vestibular symptoms to abnormal sensory processing and CGRP signaling in vestibular pathways.
PMID:42643076 SUPPORT Human Clinical
"Evidence suggests that attacks are primarily caused by abnormal central processing and integration of vestibular, visual, and nociceptive inputs, rather than by entirely peripheral labyrinthine insufficiency. Studies have identified impairments in canal-otolith integration, alterations in..."
Identifies central multisensory dysfunction in vestibulo-thalamic-cortical and cerebellar networks as the primary mechanism of vertigo in VM, rather than peripheral vestibular pathology alone.
+ 2 more references
Eye 2
Photophobia VERY_FREQUENT HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35322292 SUPPORT
"The coexistence of photophobia and headache is associated with the interactions between visual and pain pathway at retina, midbrain, thalamus, hypothalamus and visual cortex."
Describes the neuroanatomical basis for photophobia in migraine through visual-pain pathway interactions.
PMID:30982963 SUPPORT Model Organism
"Intracerebroventricular injection of CGRP induces aversion to bright or dim light in transgenic mice that overexpress the human RAMP1 subunit of the CGRP receptor"
CGRP induces light-aversive (photophobia-like) behavior in a mouse model overexpressing the human CGRP-receptor RAMP1 subunit, and olcegepant blocks it, mechanistically linking CGRP signaling to migraine photophobia.
Visual Aura OCCASIONAL Scintillating scotoma HP:0010822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual aura (scintillating scotoma), annotated with Scintillating scotoma (HP:0010822). HP:0010822 is a phenotype from the Human Phenotype Ontology.
Scintillating scotoma, fortification spectra
Show evidence (1 reference)
PMID:39080518 SUPPORT
"PET studies utilizing inflammation markers have revealed meningeal inflammatory activity in patients experiencing migraine with aura, particularly over the occipital cortex generating visual auras."
Demonstrates that visual auras in migraine are associated with inflammatory activity localized to the occipital cortex, the brain region responsible for visual processing.
Nervous System 2
Headache VERY_FREQUENT HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Unilateral, pulsating, moderate-severe
Show evidence (2 references)
PMID:37495957 SUPPORT
"In both WT and FHM1 mutant mice, CSDs induced headache-related behaviour, as evidenced by increased MGS scores and the occurrence of oculotemporal strokes, at 30 min."
Demonstrates that cortical spreading depression directly induces headache-related behaviors in animal models.
PMID:39080518 SUPPORT
"We propose that neuronal stress induced by CSD or synaptic activity-energy mismatch may initiate a parenchymal inflammatory signaling cascade, transmitted to the meninges, thereby triggering lasting headaches characteristic of migraine, with or without aura."
Explains the mechanistic pathway from neuronal stress to the characteristic lasting headaches of migraine.
Phonophobia VERY_FREQUENT HP:0002183 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Phonophobia (HP:0002183). HP:0002183 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33305448 SUPPORT
"Higher amplitudes of BAEP waves in migraineurs and their relationship with the frequency of headache and HT suggest the sensitization of brainstem auditory neurons."
Demonstrates that phonophobia in migraine is associated with sensitization of brainstem auditory neurons, as evidenced by higher brainstem auditory evoked potential amplitudes.
Constitutional 1
Cutaneous Allodynia FREQUENT HP:0012533 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cutaneous allodynia, annotated with Allodynia (HP:0012533). HP:0012533 is a phenotype from the Human Phenotype Ontology.
Periorbital and, with progression, extracephalic; a clinical marker of central sensitization during attacks
Show evidence (2 references)
PMID:30982963 SUPPORT Human Clinical
"As the migraine attack progresses, cutaneous allodynia develops in the periorbital area, signaling central sensitization of convergent TNC neurons and an increased resistance to the efficacy of triptans."
Cutaneous allodynia is a recognized migraine phenotype that develops as attacks progress, reflecting central sensitization of trigeminal nucleus caudalis neurons and predicting reduced triptan efficacy.
PMID:18427069 SUPPORT Human Clinical
"Prevalence was significantly higher in transformed migraine (TM, 68.3%) than in episodic migraine (63.2%, p < 0.01)"
In the AMPP population study, cutaneous allodynia was present in 63.2% of episodic migraine and 68.3% of transformed (chronic) migraine sufferers, supporting a FREQUENT (30-79%) frequency band.
🧬

Genetic Associations

5
CACNA1A (Causative)
Gene: CACNA1A hgnc:1388 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CACNA1A (hgnc:1388). hgnc:1388 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:32430436 SUPPORT Other
"Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion transport are implicated."
CACNA1A encodes the Cav2.1 P/Q-type voltage-gated calcium channel alpha-1A subunit; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM1 locus.
PMID:38508838 SUPPORT Other
"Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"
Establishes that rare familial migraine subtypes arise from pathogenic variants in ion-transport genes; the source does not name the individual genes, so support is PARTIAL.
ATP1A2 (Causative)
Gene: ATP1A2 hgnc:800 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ATP1A2 (hgnc:800). hgnc:800 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:32430436 SUPPORT Other
"Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion transport are implicated."
ATP1A2 encodes the alpha-2 subunit of the Na+/K+-ATPase; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM2 locus.
PMID:38508838 SUPPORT Other
"Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"
Establishes that rare familial migraine subtypes arise from pathogenic variants in ion-transport genes; the source does not name the individual genes, so support is PARTIAL.
SCN1A (Causative)
Gene: SCN1A hgnc:10585 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SCN1A (hgnc:10585). hgnc:10585 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:32430436 SUPPORT Other
"Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion transport are implicated."
SCN1A encodes the Nav1.1 voltage-gated sodium channel; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM3 locus.
PMID:38508838 SUPPORT Other
"Some distinct, rare, familial migraine subtypes are caused by pathogenic variants in genes involved in ion transport and neurotransmitter release, suggesting an underlying vulnerability of the excitatory-inhibitory balance in the brain"
Establishes that rare familial migraine subtypes arise from pathogenic variants in ion-transport genes; the source does not name the individual genes, so support is PARTIAL.
TRPM8 (Risk Factor)
Gene: TRPM8 hgnc:17961 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TRPM8 (hgnc:17961). hgnc:17961 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR
Show evidence (2 references)
PMID:21666692 SUPPORT Human Clinical
"rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5 × 10(-6)) with migraine."
GWAS identifies rs10166942 near TRPM8 as a genome-wide-significant migraine susceptibility locus, which is the risk-factor claim.
PMID:31873179 SUPPORT Human Clinical
"TRPM8 is highly expressed in migraine and pain neuronal circuitry, such as trigeminal and dorsal root ganglia"
Supports TRPM8 expression in trigeminal and dorsal root ganglion pain circuitry, providing a mechanism for the GWAS association; the snippet itself addresses expression rather than risk.
LRP1 (Risk Factor)
Gene: LRP1 hgnc:6692 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LRP1 (hgnc:6692). hgnc:6692 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR
Show evidence (2 references)
PMID:21666692 SUPPORT
"rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5 × 10(-6)) with migraine."
GWAS of 5,122 migraineurs identified LRP1 SNP rs11172113 as genome-wide significant for migraine susceptibility.
PMID:21666692 SUPPORT
"LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology."
LRP1's role in neuronal glutamate signaling provides mechanistic link to migraine.
💊

Medical Actions

11
Triptans
First-line acute treatment (sumatriptan, rizatriptan).
Show evidence (2 references)
PMID:39080518 SUPPORT
"The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."
Clinical efficacy of triptans in treating migraine attacks validates their role as first-line acute treatment.
PMID:30982963 SUPPORT Human Clinical
"Sumatriptan inhibits release of CGRP from trigeminal nerve terminals and in that study, produced parallel reductions in migraine headache pain intensity and blood levels of CGRP."
Sumatriptan reduces migraine pain in parallel with reduced blood CGRP, supporting inhibition of trigeminal CGRP release as a triptan mechanism of action.
NSAIDs
Effective for mild-moderate attacks.
Show evidence (1 reference)
PMID:27713337 SUPPORT
"NSAIDs remain the most commonly used therapies for the migraine attack. This is in part due to their wide availability as over-the-counter drugs and their pharmaco-economic advantages, but also to a favorable efficacy/side effect profile at least in attacks of mild and moderate intensity."
NSAIDs are widely used for migraine attacks due to their favorable efficacy and side effect profile, particularly for mild to moderate attacks.
CGRP Antagonists (Gepants)
Acute treatment option (ubrogepant, rimegepant).
Show evidence (2 references)
PMID:37755358 SUPPORT
"CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."
CGRP antagonists (gepants) are a class of CGRP inhibitors that have demonstrated effectiveness in migraine management.
PMID:34160823 SUPPORT Other
"Newly introduced acute treatments include two small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant, rimegepant); a serotonin (5-HT1F ) agonist (lasmiditan)"
The American Headache Society consensus statement integrates the small-molecule CGRP receptor antagonists (gepants) ubrogepant and rimegepant into acute migraine care.
Ditans (Lasmiditan)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: lasmiditan CHEBI:755069 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses lasmiditan (CHEBI:755069). CHEBI:755069 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Acute treatment option (lasmiditan, a selective 5-HT1F agonist).
Mechanism Target:
INHIBITS Trigeminovascular Activation — 5-HT1F agonism dampens trigeminal transmission centrally. Unlike the triptans, lasmiditan aborts attacks without constricting cranial vessels.
Show evidence (1 reference)
PMID:42676555 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Its efficacy supports the concept that central trigeminal modulation can abort attacks independently of vascular mechanisms."
The review reads lasmiditan's clinical efficacy as evidence that the drug acts on the trigeminal pathway itself. Indirect: therapeutic response is cited as validation of the mechanism it targets, not as a direct measurement of it.
Show evidence (2 references)
PMID:42676555 SUPPORT DIRECT REVIEW SYNTHESIS Other
"Lasmiditan, a selective 5‐HT1F agonist, is another migraine‐specific acute therapy that does not cause vasoconstriction"
States the pharmacological class and the nonvasoconstrictive property that distinguish ditans from triptans, which is what this treatment entry describes.
PMID:42676555 SUPPORT REVIEW SYNTHESIS Other
"Thus, lasmiditan is best positioned as an option for patients in whom triptans are unsuitable or ineffective."
The review authors' placement of lasmiditan in the acute-treatment sequence. This is their recommendation rather than a reported clinical result, so it is graded OTHER, matching how the sibling gepant entry grades the equivalent AHS positioning statement.
Beta Blockers
Preventive therapy (propranolol, metoprolol).
Show evidence (2 references)
PMID:30893319 SUPPORT
"Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7)."
Meta-analysis of 108 RCTs confirms propranolol efficacy for migraine prevention with high-quality evidence.
PMID:30893319 SUPPORT
"There is high quality evidence that propranolol is better than placebo for episodic migraine headache."
Systematic review establishes beta-blockers as effective first-line preventive therapy.
Topiramate
Preventive therapy.
Show evidence (2 references)
PMID:24494792 SUPPORT
"Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."
Clinical trials have established the efficacy of topiramate for migraine prevention.
PMID:24494792 SUPPORT
"Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."
Explains the mechanism by which topiramate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression.
Valproate
Preventive therapy.
Show evidence (2 references)
PMID:24494792 SUPPORT
"Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."
Clinical trials have established the efficacy of valproate/valproic acid for migraine prevention.
PMID:24494792 SUPPORT
"Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."
Explains the mechanism by which valproate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression.
CGRP Monoclonal Antibodies
Preventive therapy (erenumab, fremanezumab, galcanezumab).
Show evidence (3 references)
PMID:39080518 SUPPORT
"The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."
Anti-CGRP monoclonal antibodies have demonstrated clinical efficacy in treating migraine, supporting their use as preventive therapy.
PMID:37755358 SUPPORT
"CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."
CGRP monoclonal antibodies are CGRP inhibitors that target this key migraine pathway.
PMID:34160823 SUPPORT Other
"New preventive treatments include an intravenous anti-CGRP ligand monoclonal antibody (eptinezumab)."
The American Headache Society consensus statement adds the intravenous anti-CGRP monoclonal antibody eptinezumab to migraine preventive options.
Anti-PACAP Ligand Monoclonal Antibody
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: monoclonal antibody NCIT:C20401 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses monoclonal antibody (NCIT:C20401). NCIT:C20401 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
Investigational preventive therapy directed at the PACAP ligand (Lu AG09222), the most advanced non-CGRP neuropeptide class. Phase 2 only; not an approved treatment.
Mechanism Target:
INHIBITS PACAP Pathway — Sequestering the PACAP ligand blocks the pathway upstream of all three PACAP receptors, which is the join point between this treatment and the PACAP mechanism node.
Show evidence (1 reference)
PMID:42676555 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Ligand‐directed approaches now appear more promising than receptor‐selective blockade, since a monoclonal antibody against the PAC1 receptor failed clinically, whereas the anti‐PACAP ligand antibody Lu AG09222 showed Phase 2 efficacy in reducing monthly migraine days"
Phase 2 efficacy of ligand sequestration is cited as validation of the PACAP pathway it targets. Indirect: therapeutic response stands in for a direct measurement of the mechanism.
Show evidence (1 reference)
PMID:42676555 SUPPORT REVIEW SYNTHESIS Other
"PACAP‐targeted therapies are the most advanced emerging class and provide proof of principle that migraine can be modified through non‐CGRP neuropeptide pathways"
Establishes the class as the leading non-CGRP neuropeptide option, which is what this treatment record is for.
Botulinum Toxin
For chronic migraine prevention.
Show evidence (1 reference)
PMID:38910144 SUPPORT
"Among all the drugs for the preventive drugs for CM, Botulinum toxin A has the best efficacy and safety profile, closely followed by calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)."
Network meta-analysis of 24 RCTs demonstrates botulinum toxin A has the best efficacy and safety profile among chronic migraine preventive treatments.
Neuromodulation
Non-invasive devices for prevention and acute treatment.
Show evidence (1 reference)
PMID:37755358 SUPPORT
"Finally, the paper delves into neuromodulation as an innovative treatment modality. Clinical studies indicating its effectiveness in migraine management are reviewed"
Clinical studies have demonstrated the effectiveness of neuromodulation devices in migraine management.
🌍

Environmental Factors

6
Stress
psychological stress XCO:0001265 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is psychological stress, annotated with stress (XCO:0001265). XCO:0001265 is an exposure from the Experimental Conditions Ontology.
Common trigger
Show evidence (2 references)
PMID:35143379 SUPPORT
"Both mental/cognitive stress and daily stress (perceived) were related to an increase in pain perception and related to the development of headache or enhanced transient pain intensity in migraine and TTH patients."
Systematic review confirms stress as a trigger for migraine headaches.
PMID:1525797 SUPPORT
"In both MA and MO the most conspicuous precipitating factor was stress and mental tension."
Epidemiological study identifies stress as the most common precipitating factor for both migraine subtypes.
Sleep Disturbance
disturbed sleep XCO:0001068 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is disturbed sleep, annotated with sleep (XCO:0001068). XCO:0001068 is an exposure from the Experimental Conditions Ontology.
Both insufficient and excessive sleep are commonly reported migraine triggers; disrupted sleep-wake regulation is one of the recognised precipitating factors for attacks.
Show evidence (1 reference)
PMID:28436283 SUPPORT Human Clinical
"Lack of sleep (51.4%), stress (44.6%), warm climate (41.9%), noise (32.4%), and excitation (29.7%) were the most frequently reported"
Prospective 3-month trigger diary in 101 paediatric migraine patients; lack of sleep was the single most frequently reported trigger. PARTIAL because it evidences insufficient sleep only, not the excessive-sleep half of this annotation, and the cohort is paediatric.
Hormonal Changes
Menstruation, oral contraceptives
Show evidence (3 references)
PMID:19076658 SUPPORT
"The trigger thought to be partially responsible for menstrually associated migraine is a significant drop in circulating estrogen that is noted during 2-3 days prior to onset of menses."
Estrogen withdrawal is established as the hormonal trigger for menstrual migraine.
PMID:19076658 SUPPORT
"It is estimated that approximately 50% of women have an increased risk of experiencing migraine during the premenstrual phase of decreasing estrogen levels."
Half of female migraineurs have increased risk during premenstrual estrogen decline.
PMID:1525797 SUPPORT
"Onset at menarche, menstrual precipitation, menstrual problems, influence of pregnancy and use of oral contraceptives all showed some relationship with the presence of MO and less with MA."
Population study confirms hormonal factors including menstruation and oral contraceptives as migraine triggers.
Dietary Triggers
Caffeine withdrawal and alcohol have provocation-study support; chocolate and aged cheese are commonly cited but poorly supported
Show evidence (2 references)
PMID:27699780 SUPPORT Human Clinical
"Caffeine withdrawal and administration of MSG (dissolved in liquid) has the strongest evidence for triggering attacks of headache as evidenced by multiple positive provocation studies"
Narrative review grading the evidence per food. Caffeine withdrawal is the best-supported dietary trigger, resting on positive provocation studies rather than patient self-report.
PMID:15806385 REFUTE Human Clinical
"the importance of chocolate has been doubted seriously, and scientific evidence for cheese as a precipitating factor is lacking"
Refutes two of the four items the note previously listed. The note has been rewritten accordingly: alcohol and caffeine withdrawal are retained as controlled-trial-supported precipitants, while chocolate and aged cheese are marked as commonly cited but poorly supported. This is the same correction pattern as Celiac early-gluten-introduction in tranche 1.
Mechanism Target:
TRIGGERS Headache — Caffeine withdrawal and monosodium glutamate provoke migraine attacks in controlled provocation studies.
Show evidence (1 reference)
PMID:27699780 SUPPORT DIRECT Human Clinical
"Caffeine withdrawal and administration of MSG (dissolved in liquid) has the strongest evidence for triggering attacks of headache as evidenced by multiple positive provocation studies"
Provocation studies are experimental rather than self-reported, which is what makes this a trigger claim rather than an association. The edge jumps the cortical-spreading-depression and trigeminovascular nodes through which a provoked attack proceeds. Scoped to caffeine withdrawal and MSG: the entry's own REFUTE item withdraws chocolate and aged cheese.
Weather Changes
weather change exposure ECTO:1000020 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is weather change exposure, annotated with exposure to weather (ECTO:1000020). ECTO:1000020 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Barometric pressure changes
Show evidence (1 reference)
PMID:36853848 SUPPORT Human Clinical
"we found that low barometric pressure, barometric pressure changes, higher humidity, and rainfall were associated with an increased number of headache occurrences"
Smartphone-diary study of 336,951 hourly headache events, which is the scale this question has historically lacked -- the paper's own background notes the weather-headache relationship remained unknown. PARTIAL because the outcome is headache occurrence across a mixed cohort (37.2% physician-diagnosed migraine) rather than migraine attacks specifically.
Sensory Stimuli
Noise is the sensory trigger with prospective diary support; bright lights and strong odours are commonly cited but not evidenced here
Show evidence (1 reference)
PMID:28436283 SUPPORT Human Clinical
"Lack of sleep (51.4%), stress (44.6%), warm climate (41.9%), noise (32.4%), and excitation (29.7%) were the most frequently reported"
Prospective trigger diary in which noise was reported before a third of attacks, establishing sensory stimuli as a precipitant. PARTIAL because the diary evidences noise only; the bright lights and strong odours also named on this exposure are unevidenced here, and a light/odour-specific source was searched for and not found.
🔬

Biochemical Markers

2
CGRP (Elevated)
Context: During attacks
Show evidence (3 references)
PMID:37755358 SUPPORT
"Special emphasis is given to the role of calcitonin gene-related peptide (CGRP) in migraine development. CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."
Confirms the central role of CGRP in migraine pathophysiology and its elevation during attacks.
PMID:30982963 SUPPORT Human Clinical
"Several studies demonstrated that blood levels of CGRP obtained from the jugular vein of people with migraine are elevated during a migraine attack."
Jugular venous CGRP is elevated during migraine attacks, directly supporting CGRP elevation during the ictal phase.
PMID:30982963 SUPPORT Human Clinical
"the interictal levels of CGRP of people with chronic migraine are significantly elevated when compared to those of patients with episodic migraine, and it was suggested that these elevated interictal CGRP levels in people with migraine could be a biomarker aiding the diagnosis of chronic migraine."
Interictal CGRP is elevated in chronic versus episodic migraine and has been proposed as a diagnostic biomarker of chronic migraine.
Serotonin (Decreased)
Context: May contribute to attacks
Show evidence (2 references)
PMID:17970989 SUPPORT
"Amongst the many neurotransmitters in the brain, the serotonergic (serotonin, 5-HT) system from the brainstem raphe nucleus has been most convincingly implicated in migraine pathophysiology."
Serotonergic system is the most convincingly implicated neurotransmitter system in migraine.
PMID:17970989 SUPPORT
"The documented changes in 5-HT metabolism and in the processing of central 5-HT-mediated responses during and in between migraine attacks have led to the suggestion that migraine is a consequence of a central neurochemical imbalance that involves a low serotonergic disposition."
Low serotonin disposition is associated with migraine susceptibility and attacks.
📊

Related Datasets

4
DNA methylation in episodic migraine and medication overuse headache. geo:GSE318177
These data were generated within the Epimode project - a pilot, longitudinal, prospective, observational study designed to investigate DNA methylation in headache disorders. 20 episodic migraineurs (EM), 25 medication overuse headache patients (MOH) and 13 healthy controls (HC) were enrolled in the study. EM and HC samples were collected at baseline (T0) and ath the follow-up visit 6 months later (T1). MOH samples were collected at baseline (T0), at treatment time point (T1) and at the follow-up visits after 2 (T2) and 6 (T3) months from the therapeutic intervention.
human METHYLATION n=142
PMID:41721229
Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine geo:GSE197289
The sensitization of trigeminal ganglion neurons contributes to primary headache disorders such as migraine, but the specific neuronal and non-neuronal trigeminal subtypes involved remain unclear. We thus developed a cell atlas in which human and mouse trigeminal ganglia are transcriptionally and epigenomically profiled at single-cell resolution. These data describe evolutionarily conserved and human-specific gene expression patterns within each trigeminal ganglion cell type, as well as the transcription factors and gene regulatory elements that contribute to cell-type-specific gene expression.
SINGLE CELL RNA SEQ n=36
PMID:35349784
Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. GEO reports both Homo sapiens and Mus musculus; structured organism is omitted because Dataset.organism is single-valued.
Multiomic-based Immune Response Profiling in Migraine, Vestibular Migraine and Meniere's Disease geo:GSE269117
We analysed the immune profile of individuals with MI, VM, and MD using scRNAseq and scATACseq in PBMCs and to determine active biochemical pathways to identify new potential druggable molecular targets
human MULTI OMICS n=24
PMID:39294737
Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
RNA sequencing of spontaneous migraine attacks ega:EGAS00001006795
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Migraine"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
🔬

Clinical Trials

3
NCT07040813 PHASE_III RECRUITING
A randomized placebo-controlled double-blind trial investigating the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal antibody therapy for chronic migraine prevention over 12 weeks. The study evaluates dual therapy versus CGRP monoclonal antibody monotherapy in reducing monthly migraine days.
Target Phenotypes: Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology. Nausea HP:0002018 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Nausea (HP:0002018). HP:0002018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT07040813 SUPPORT
"The study will evaluate the efficacy of onabotulinumtoxin A when added to CGRP monoclonal antibody therapy in chronic migraine prevention. Adverse events and change in disease activity will be monitored."
This Phase III trial directly evaluates a combination approach targeting two major migraine pathways (CGRP and acetylcholine) for chronic migraine prevention.
NCT06241313 PHASE_III RECRUITING
Randomized, double-blind, placebo-controlled, multiple-attack study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and consistency of effect with an open-label extension phase.
Target Phenotypes: Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology. Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology. Phonophobia HP:0002183 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Phonophobia (HP:0002183). HP:0002183 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06241313 SUPPORT
"The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly."
This Phase III trial evaluates atogepant, a CGRP antagonist, for acute migraine treatment, providing clinical evidence for transitioning this preventive agent to acute attack management.
NCT07061847 PHASE_II RECRUITING
Study evaluating bilateral middle meningeal artery (MMA) lidocaine infusion as a novel interventional approach for chronic debilitating migraines. Investigates localized anesthesia targeting the pain-sensitive meningeal tissues implicated in migraine pathophysiology.
Target Phenotypes: Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT07061847 SUPPORT
"The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine..."
This Phase II trial investigates a novel interventional procedure targeting meningeal pain pathways in chronic migraine, providing clinical evidence for direct vascular intervention approaches.
{ }

Source YAML

click to show 
name: Migraine
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Migraine is a common chronic neurological disorder characterized by recurrent
  attacks of moderate-to-severe, often unilateral pulsating headache accompanied by
  nausea, photophobia, and phonophobia, occurring with or without aura. Its
  pathophysiology involves cortical spreading depression (the substrate of aura),
  activation and sensitization of the trigeminovascular system, and release of
  vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP).
category: Complex
parents:
- Neurological Disease
disease_term:
  preferred_term: migraine disorder
  term:
    id: MONDO:0005277
    label: migraine disorder
has_subtypes:
- name: Migraine with Aura
  description: Preceded by transient neurological symptoms (visual, sensory,
    speech).
  evidence:
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "Lifetime prevalence of MA was 5%, male:female ratio 1:2."
    explanation: Population study establishes migraine with aura as a distinct
      subtype with 5% lifetime prevalence.
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "Visual disturbances were the most common aura phenomenon occurring in
      90% of subjects with MA."
    explanation: Visual symptoms are the predominant aura type, occurring in 90%
      of migraine with aura cases.
- name: Migraine without Aura
  description: Most common form, no preceding aura.
  evidence:
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "Lifetime prevalence of MO was 8%, M:F ratio 1:7."
    explanation: Migraine without aura is the most common form with 8% lifetime
      prevalence and strong female predominance.
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "Women, but not men, were significantly more likely to have MO than MA."
    explanation: Migraine without aura shows stronger female predominance than
      migraine with aura.
- name: Chronic Migraine
  description: >-
    Headache on 15 or more days per month for more than 3 months, of which at
    least 8 days have migraine features - the ICHD-3 diagnostic threshold that
    separates chronic from episodic migraine.
  evidence:
  - reference: PMID:30893319
    reference_title: "Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For chronic migraine, propranolol was more likely to reduce headaches
      by at least 50% (RR: 2.0, 95% CI: 1.0-4.3)."
    explanation: Analysed separately from episodic migraine in this meta-analysis,
      supporting chronic migraine as a distinct treatment population; the snippet
      does not state the diagnostic day-count criterion.
- name: Vestibular Migraine
  description: >-
    Migraine with prominent vestibular symptoms (vertigo, dizziness) occurring
    with or without headache. Characterized by recurrent episodes of moderate to
    severe vestibular symptoms (spontaneous, positional, visually-induced, or
    head-motion-induced vertigo/dizziness) lasting 5 minutes to 72 hours, with
    migraine-associated features such as photophobia, phonophobia, and nausea.
    Underlies abnormal central integration of vestibular, visual, and
    nociceptive inputs due to trigemino-vestibular pathway dysfunction. Central
    dysfunction is the primary mechanism but not the only one: peripheral
    vestibular abnormalities on vHIT or caloric testing are present in a subset
    of patients, so the source concludes vestibular migraine should not be read
    as a purely central disorder in every case.
  evidence:
  - reference: PMID:38619053
    reference_title: "Vestibular migraine: an update."
    supports: SUPPORT
    snippet: "Vestibular migraine is an underdiagnosed migraine phenotype that shares
      the pathophysiological mechanisms of migraine, with growing interest in recent
      years."
    explanation: Vestibular migraine is established as a distinct underdiagnosed
      migraine phenotype.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Vestibular migraine should be approached as a multisystem neurovestibular disorder rather than a simple coexistence of migraine and vertigo."
    explanation: >-
      The review's own recommendation, quoted as the source sentence behind this
      subtype's multisystem framing. Graded OTHER rather than HUMAN_CLINICAL
      because the quoted text is the authors' synthesis and recommendation over
      the literature, not an observation in a patient cohort.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Current evidence supports vestibular migraine as a complex disorder involving trigeminovascular activation, CGRP signaling, central sensitization, vestibulo-thalamo-cortical networks, and cerebellar compensation."
    explanation: >-
      Systematic review of 72 studies affirms the multisystem neurovestibular
      nature of vestibular migraine, involving trigemino-vestibular interactions
      and central network dysfunction beyond simple coexistence of migraine and
      vertigo.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Attacks are primarily caused by abnormal central processing and integration of vestibular, visual, and nociceptive inputs, rather than by entirely peripheral labyrinthine insufficiency."
    explanation: >-
      Establishes central multisensory dysfunction as the primary mechanism,
      qualified by the peripheral-abnormality subgroup recorded below,
      involving vestibulo-thalamo-cortical networks, rather than isolated
      peripheral vestibular pathology.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of peripheral vestibular abnormalities in vHIT or caloric tests in some patients indicates that VM should not be interpreted as a purely central disorder in all patients"
    explanation: >-
      The source's own counterbalance to the central framing above. Cited so the
      subtype description's "not the only one" qualifier rests on the review's
      stated conclusion rather than on the curator's reading of it.
mechanistic_hypotheses:
- hypothesis_group_id: csd_initiated_migraine
  hypothesis_label: CSD-Initiated Migraine (Aura Pathway)
  status: CANONICAL
  description: >-
    In migraine with aura, cortical spreading depression (CSD) — a slowly
    propagating wave of neuronal and glial depolarization — initiates the aura
    phase and drives downstream trigeminovascular activation. CSD releases
    inflammatory mediators (HMGB1, ATP, prostaglandins) via pannexin-1 channels,
    which sensitize meningeal trigeminal afferents, trigger CGRP release from
    peripheral and central trigeminal terminals, and culminate in the headache
    phase. The premonitory hypothalamic/brainstem network may lower the CSD
    threshold. This pathway is well established in animal models and supported
    by the efficacy of CGRP-targeting therapies in both aura and non-aura forms.
  evidence:
  - reference: PMID:37495957
    reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cortical spreading depolarization (CSD), the neurophysiological correlate
      of the migraine aura, can activate trigeminal pain pathways, but the neurobiological
      mechanisms and behavioural consequences remain unclear."
    explanation: >
      Establishes CSD as the neurophysiological basis of migraine aura and its
      downstream role in activating trigeminal pain pathways, supporting the
      CSD-initiated migraine hypothesis.
  - reference: PMID:29697154
    reference_title: "A Phase-by-Phase Review of Migraine Pathophysiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In one-third of patients, an aura phase may occur during some attacks and likely correlates with a cortical spreading depression-like event; a slowly propagating wave of neuronal and glial cell depolarization and hyperpolarization."
    explanation: >
      Phase-by-phase review establishes CSD as the mechanistic basis of aura in
      one-third of migraine attacks, supporting the CSD-initiated pathway.
- hypothesis_group_id: brainstem_hypothalamic_migraine
  hypothesis_label: Brainstem/Hypothalamic-Initiated Migraine (Non-Aura Pathway)
  status: EMERGING
  description: >-
    In migraine without aura — the most common form — headache initiates without
    evident CSD. Instead, premonitory activation of hypothalamic and brainstem
    circuits (locus coeruleus, dorsal raphe, periaqueductal gray) modulates
    trigeminal nucleus caudalis excitability, lowering the threshold for
    trigeminovascular activation. The hypothalamic premonitory network directly
    sensitizes the trigeminovascular pathway via descending modulation, leading
    to CGRP release and headache without a cortical CSD step. This pathway
    explains the premonitory symptoms (fatigue, yawning, food cravings) that
    precede headache onset by up to 72 hours.
  evidence:
  - reference: PMID:29697154
    reference_title: "A Phase-by-Phase Review of Migraine Pathophysiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The premonitory phase begins as early as 3 days before the headache phase, and involves a complex interplay between various cortical and subcortical brain regions, including the hypothalamus and brainstem nuclei that modulate nociceptive signaling. The headache phase involves activation of the trigeminovascular system, a pathway that is well characterized."
    explanation: >
      Establishes that the premonitory hypothalamic/brainstem network drives
      trigeminovascular activation in migraine, supporting an initiation pathway
      that operates independent of overt CSD.
pathophysiology:
- name: Cortical Spreading Depression
  description: >
    Wave of neuronal depolarization spreading across cortex underlies
    aura. Triggers activation of trigeminal pathways and may initiate
    headache phase.
  biological_processes:
  - preferred_term: Neural Signaling
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:37495957
    reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
    supports: SUPPORT
    snippet: "Cortical spreading depolarization (CSD), the neurophysiological correlate
      of the migraine aura, can activate trigeminal pain pathways, but the neurobiological
      mechanisms and behavioural consequences remain unclear."
    explanation: Establishes CSD as the neurophysiological basis of migraine
      aura and its role in activating trigeminal pain pathways.
  - reference: PMID:37495957
    reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In both WT and FHM1 mutant mice, CSDs induced headache-related behaviour,
      as evidenced by increased MGS scores and the occurrence of oculotemporal strokes,
      at 30 min."
    explanation: Demonstrates that CSDs directly induce headache-related
      behaviors in animal models, supporting CSD's role in headache initiation.
  - reference: PMID:37495957
    reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Blocking Panx1 channels by TAT-Panx308 inhibited CSD-induced headache
      related behaviour and HMGB1 release."
    explanation: Shows that pannexin-1 channels mediate CSD-induced
      neuroinflammatory signaling and headache behaviors, identifying a key
      mechanism linking CSD to pain.
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "Neuronal pannexin-1 channels act as stress sensors, initiating the inflammatory
      signaling by inflammasome formation and high-mobility group box-1 release in
      response to transient perturbations such as cortical spreading depolarization
      (CSD)"
    explanation: Explains the molecular mechanism by which CSD triggers
      neuroinflammation through pannexin-1 channels and HMGB1 release.
  downstream:
  - target: Trigeminovascular Activation
    causal_link_type: DIRECT
    hypothesis_groups:
    - csd_initiated_migraine
    description: >
      CSD releases inflammatory mediators (HMGB1, prostaglandins) via pannexin-1
      channels and activates meningeal trigeminal nociceptors, driving the
      trigeminovascular activation that initiates the headache phase.
    evidence:
    - reference: PMID:37495957
      reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Blocking Panx1 channels by TAT-Panx308 inhibited CSD-induced headache related behaviour and HMGB1 release."
      explanation: >
        Mouse CSD perturbation evidence supports pannexin-1/HMGB1 signaling as a
        mechanistic bridge between CSD and headache-relevant trigeminal pathway
        activation.
- name: Trigeminovascular Activation
  description: >
    Activation of trigeminal nerve fibers innervating meningeal blood
    vessels releases CGRP and other neuropeptides, causing neurogenic
    inflammation and pain.
  biological_processes:
  - preferred_term: Pain Signaling
    term:
      id: GO:0048265
      label: response to pain
  genes:
  - preferred_term: TRPM3
    term:
      id: hgnc:17992
      label: TRPM3
    description: >-
      Hormone-sensitive channel expressed in trigeminovascular tissues and
      proposed as a modulator of sex-related differences in trigeminovascular
      excitability. Recorded here as an expression-level mechanistic
      contributor, not as a genetic risk factor: the cited source reports no
      variant association and frames the pathway as emerging rather than
      definitive.
  evidence:
  - reference: PMID:37487740
    reference_title: "Meningeal P2X7 Signaling Mediates Migraine-Related Intracranial Mechanical Hypersensitivity."
    supports: SUPPORT
    snippet: "CSD is also thought to drive the headache phase in migraine by promoting
      the activation and mechanical sensitization of trigeminal primary afferent nociceptive
      neurons that innervate the cranial meninges."
    explanation: Confirms that CSD drives trigeminovascular activation leading
      to headache phase in migraine.
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Studies in rodents have demonstrated that sterile meningeal inflammation
      can stimulate and sensitize meningeal nociceptors, culminating in headaches."
    explanation: Shows that meningeal inflammation activates and sensitizes
      trigeminal nociceptors, producing headache.
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "The parenchymal neuroinflammatory signaling involving neurons, astrocytes,
      and microglia, which eventually extends to the meninges, can link non-homeostatic
      perturbations in the insensate brain to pain-sensitive meninges."
    explanation: Describes the pathway by which brain parenchymal inflammation
      extends to activate pain-sensitive meningeal structures and trigeminal
      afferents.
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "TRPM3 channels, which are expressed in trigeminovascular tissues, have also emerged as candidate modulators of sex-related differences in trigeminovascular excitability and may interact with CGRP signaling, potentially contributing to the higher prevalence and severity of migraine in females"
    explanation: >
      Sources the TRPM3 gene descriptor on this node. The claim is expression
      and candidate modulation of trigeminovascular excitability, which is a
      mechanistic contribution to this node rather than a variant association,
      and the source states it as a candidate, so the quote reaches the claim
      by an inference step.
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "However, these pathways should be framed as emerging rather than definitive explanations for female predominance in migraine."
    explanation: >
      The review's own hedge on the sex-related mechanisms including TRPM3,
      recorded here so the descriptor is not read as an established
      determinant.
  downstream:
  - target: PACAP Pathway
    causal_link_type: DIRECT
    description: >
      Activated trigeminal afferents release PACAP alongside CGRP, so
      trigeminovascular activation feeds the PACAP arm as well as the CGRP one.
    evidence:
    - reference: PMID:42676555
      reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "Pituitary adenylate cyclase-activating polypeptide (PACAP) is another important neuropeptide within the trigeminovascular network and, like CGRP, can provoke migraine in susceptible individuals"
      explanation: >
        Places PACAP inside the trigeminovascular network this node describes,
        parallel to CGRP, which is the edge asserted here.
  - target: CGRP Pathway
    causal_link_type: DIRECT
    description: >
      Activated trigeminal afferents release CGRP from peripheral nerve and central
      nerve terminals, initiating vasodilation and neurogenic inflammation in the
      meninges.
    evidence:
    - reference: PMID:30982963
      reference_title: "CGRP and the Trigeminal System in Migraine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The neuropeptide CGRP is abundant in trigeminal ganglion neurons, and is released from the peripheral nerve and central nerve terminals as well as being secreted within the trigeminal ganglion."
      explanation: >
        Establishes that CGRP release from activated trigeminal afferents is the
        mechanistic link between trigeminovascular activation and the CGRP pathway.
  - target: Trigemino-Vestibular Pathway
    causal_link_type: DIRECT
    description: >-
      Trigeminovascular activation during an attack reaches structures
      anatomically and functionally linked to the vestibular system, not only
      the pain pathways, which is the upstream entry point for the vestibular
      arm of this entry.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "During a migraine attack, trigeminovascular activation and CGRP release may affect not only pain pathways but also structures anatomically and functionally linked to the vestibular system."
      explanation: >-
        States the link this edge asserts: the same trigeminovascular activation
        that drives headache also reaches vestibular structures. The source's
        "may affect" hedge is why `causal_link_type` is the only strength claim
        made here.
- name: Central Sensitization
  description: >
    Repeated activation leads to sensitization of trigeminal nucleus
    and thalamic neurons, producing allodynia and enhanced pain
    perception.
  evidence:
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      progresses from peripheral sensitization of the primary afferent TG neurons
      to central sensitization of TNC second-order neurons and ultimately to
      central sensitization of third-order neurons in the thalamus.
    explanation: >-
      Directly states the node's claim - sensitization of trigeminal nucleus
      caudalis second-order neurons and of thalamic third-order neurons, which is
      what distinguishes central from peripheral sensitization.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As the migraine attack progresses, cutaneous allodynia develops in the
      periorbital area, signaling central sensitization of convergent TNC neurons and
      an increased resistance to the efficacy of triptans."
    explanation: >-
      Links the allodynia asserted by this node to central sensitization of
      convergent TNC neurons in patients during attacks.
  - reference: PMID:37487740
    reference_title: "Meningeal P2X7 Signaling Mediates Migraine-Related Intracranial Mechanical Hypersensitivity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Broad-spectrum P2X receptor inhibition, selective blockade of the P2X7
      receptor, and its related Pannexin 1 channel suppressed CSD-evoked afferent
      mechanical sensitization but did not affect the accompanying afferent activation
      response."
    explanation: >-
      Support is PARTIAL because this addresses mechanical sensitization of
      meningeal primary afferents - the peripheral limb that feeds central
      sensitization - not sensitization of the second- and third-order CNS neurons
      this node describes.
- name: CGRP Pathway
  description: >
    Calcitonin gene-related peptide (CGRP) release from trigeminal
    neurons causes vasodilation and neurogenic inflammation. CGRP
    blockers are effective treatments.
  evidence:
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin
      gene-related peptide antibodies and triptans in treating migraine attacks, both
      with and without aura, supports the concept of migraine pain originating in
      meninges."
    explanation: Clinical efficacy of CGRP-targeting therapies validates the
      central role of the CGRP pathway in migraine pathophysiology.
  - reference: PMID:37569648
    reference_title: "Migraine Treatment: Towards New Pharmacological Targets."
    supports: SUPPORT
    snippet: "However, the progresses in unravelling the migraine pathophysiology
      allowed identifying novel putative targets as calcitonin gene-related peptide
      (CGRP)."
    explanation: Identifies CGRP as a key validated target in migraine treatment
      based on understanding of disease pathophysiology.
  - reference: PMID:37569648
    reference_title: "Migraine Treatment: Towards New Pharmacological Targets."
    supports: SUPPORT
    snippet: "Nevertheless, despite the revolution brought by CGRP monoclonal antibodies
      and gepants, a significant percentage of patients still remains burdened by
      an unsatisfactory response, suggesting that other pathways may play a critical
      role"
    explanation: Notes that while CGRP pathway is important, treatment
      resistance in some patients indicates involvement of additional pathways
      beyond CGRP.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The i.v. infusion of CGRP produces a delayed migraine attack in a
      majority of individuals with a past history of migraine."
    explanation: Intravenous CGRP provokes delayed migraine attacks in people with
      a history of migraine (but not in healthy controls), providing direct causal
      evidence that CGRP drives migraine.
  downstream:
  - target: Central Sensitization
    causal_link_type: DIRECT
    description: >
      Peripheral CGRP release perpetuates trigeminal nerve sensitization and drives
      central sensitization of second-order neurons in the trigeminal nucleus
      caudalis and thalamus, producing allodynia and enhanced pain perception.
    evidence:
    - reference: PMID:30982963
      reference_title: "CGRP and the Trigeminal System in Migraine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "A shift in central sensitization from activity-dependent to activity-independent central sensitization may indicate a mechanism driving the progression of episodic migraine to chronic migraine."
      explanation: >
        Identifies CGRP-driven central sensitization and its activity-dependent
        to activity-independent shift as the mechanism linking the CGRP pathway
        to chronic central sensitization and migraine chronification.
  - target: Vestibular CGRP Signaling
    causal_link_type: DIRECT
    description: >-
      CGRP released during the attack acts on trigeminal terminals innervating
      inner ear structures and on CGRP receptors in the vestibular nuclei, so
      the same peptide that drives the pain arm also drives the vestibular one.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Trigeminal innervation and CGRP expression in inner ear structures are interpreted as a biological bridge between migraine biology and otologic/vestibular symptoms."
      explanation: >-
        Names CGRP expression at trigeminal terminals in inner ear structures as
        the bridge between migraine biology and vestibular symptoms, which is
        the edge from the general CGRP pathway into its vestibular branch.
- name: Trigemino-Vestibular Pathway
  description: >-
    Glutamatergic projections from the caudal trigeminal nucleus directly
    innervate vestibular nuclei. During migraine attacks, trigeminal nociceptive
    activation and CGRP release from trigeminal terminals drive vestibular
    nucleus sensitization, generating central vestibular hypersensitivity.
    This pathway is the mechanistic bridge linking migraine biology to
    vestibular symptoms in vestibular migraine.
  biological_processes:
  - preferred_term: Nociceptive Signaling
    term:
      id: GO:0048265
      label: response to pain
  - preferred_term: Glutamatergic Synaptic Transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
  evidence:
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The trigemino-vestibular projection is glutamatergic, originates in the caudal trigeminal nucleus, and projects to the vestibular nuclei, where it mediates vestibular dysfunction in chronic nitroglycerin migraine models; silencing this projection reduces vestibular dysfunction."
    explanation: >-
      Mechanistic evidence from chronic migraine animal models demonstrates that
      glutamatergic trigemino-vestibular projections drive vestibular nucleus
      sensitization and that blocking them rescues vestibular dysfunction.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Trigeminal nociceptive pathways interact with vestibular nuclei, which generate central sensitivity during attacks. Experimental models demonstrate both glutamatergic projections from the caudal trigeminal nucleus to the vestibular nuclei and increased neuronal activation in vestibular centers following migraine provocation."
    explanation: >-
      Shows that trigeminal-vestibular interactions produce central vestibular
      sensitization, with increased neuronal activation in vestibular nuclei
      during migraine-like activation.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Following chronic migraine paradigms, abnormal synaptic protein expression and altered synaptic morphology have been reported in the vestibular nucleus, consistent with central sensitization processes."
    explanation: >-
      Demonstrates that chronic migraine triggers synaptic plasticity changes
      in the vestibular nucleus, supporting a central sensitization mechanism
      in vestibular migraine.
  downstream:
  - target: Vestibulo-Thalamo-Cortical Dysfunction
    causal_link_type: DIRECT
    description: >-
      Sensitized vestibular nuclei drive abnormal activity and altered
      multisensory integration in the vestibulo-thalamo-cortical networks,
      causing impaired balance between vestibular, visual, and auditory
      inputs. This produces motion intolerance, visual motion sensitivity,
      and vertigo.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      snippet: "Functional imaging and physiological data support a modulation disorder in multimodal cortical networks that normally balance vestibular with visual/auditory cues, a condition that causes motion intolerance and vertigo."
      explanation: >-
        Links trigemino-vestibular activation to altered thalamo-cortical
        networks responsible for integrating vestibular, visual, and auditory
        inputs, explaining vestibular migraine vertigo and motion sensitivity.
- name: Vestibulo-Thalamo-Cortical Dysfunction
  description: >-
    Abnormal modulation within multimodal cortical networks (temporo-parieto-insular
    vestibular cortex, thalamus, visual cortex) due to sensitized
    vestibular/trigeminal input. Impaired reciprocal inhibition between visual
    and vestibular systems causes visual motion sensitivity and vertigo. Central
    sensitization of thalamocortical networks produces widespread sensory
    hypersensitivity (allodynia, tinnitus, visual/auditory oversensitivity).
  notes: >-
    `biological_processes` is deliberately left unbound. GO has no term for the
    cortical multisensory integration this node models: searching GO for
    "multisensory integration", "sensory integration", and "sensory processing"
    returns only neuromuscular and sensory-perception terms, none of which
    denote the thalamo-cortical integration of vestibular with visual and
    auditory cues. The slot previously carried `GO:0050905`, whose canonical
    label is "neuromuscular process" and which therefore asserted a
    neuromuscular claim this node does not make. GO is also scoped to molecular
    and cellular processes rather than the system-level physiology described
    here, so an NTR would be needed before this can be bound correctly.
  biological_processes:
  - preferred_term: Multisensory Integration
    description: >-
      Thalamo-cortical integration of vestibular, visual, and auditory signals.
      Unbound - see this node's `notes` for why no GO term applies.
  evidence:
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disruption of reciprocal inhibition between the visual and vestibular systems may explain visual motion sensitivity and vertigo-like visual symptoms."
    explanation: >-
      Imaging evidence shows that vestibular migraine attacks involve disrupted
      visual-vestibular balance, explaining visual motion sensitivity and vertigo.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central sensitization is an increasingly important mechanism in VM. Phenotypes associated with widespread cutaneous allodynia, sleep disturbances, tinnitus, depressive symptoms, and high disability can be interpreted as clinical manifestations of increased sensitivity in thalamocortical sensory processing."
    explanation: >-
      Establishes that vestibular migraine phenotypes with widespread
      multisensory hypersensitivity (allodynia, tinnitus, auditory/visual
      oversensitivity) reflect central sensitization in thalamocortical networks.
  downstream:
  - target: Vertigo
    causal_link_type: DIRECT
    description: >-
      Abnormal vestibulo-thalamo-cortical integration produces vestibular symptoms
      (spontaneous, positional, visually-induced, or head-motion-induced vertigo/dizziness)
      that may occur with or without headache during vestibular migraine attacks.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      snippet: "Evidence suggests that attacks are primarily caused by abnormal central processing and integration of vestibular, visual, and nociceptive inputs, rather than by entirely peripheral labyrinthine insufficiency."
      explanation: >-
        Demonstrates that vertigo in vestibular migraine arises from central
        dysfunction of multisensory integration networks rather than peripheral
        labyrinthine pathology alone.
- name: Vestibulo-Cerebellar Integration Failure and Compensation
  description: >-
    The vestibulocerebellum and deep cerebellar nuclei are among the sites where
    vestibular and trigeminal nociceptive signals converge, and they carry the
    canal-otolith integration that builds a stable percept of head orientation.
    Defective central synthesis of cerebellar origin is inferred from raised
    thresholds and delayed tilt perception under combined canal-otolith
    stimulation. The same networks are the substrate for recovery: cerebellar
    functional activity changes after vestibular rehabilitation, which is why
    this node carries both the deficit and the compensation it permits. This is
    the fifth of the five mechanism families the source's own summary names, and
    it is the one that makes vestibular rehabilitation mechanistically
    intelligible rather than merely empirical.
  role: amplifier
  biological_scale: TISSUE
  locations:
  - preferred_term: vestibulocerebellum
    term:
      id: UBERON:0014642
      label: vestibulocerebellum
  evidence:
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The brainstem and cerebellar nuclei, vestibular nuclei, and vestibulocerebellum have repeatedly been identified as sites where vestibular and nociceptive (trigeminal) signals interact; this interaction may trigger vestibular symptoms in migraine episodes"
    explanation: >-
      Establishes the cerebellar nuclei and vestibulocerebellum as convergence
      sites for vestibular and trigeminal nociceptive signals, which is the
      anatomical claim this node rests on.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Patients with abnormal integration exhibit reduced motion detection thresholds and delayed formation of tilt perceptions during combined canal-otolith stimulation; this likely implies central synthesis defects of cerebellar"
    explanation: >-
      The psychophysical measurement behind the deficit half of this node.
      Graded INDIRECT because the cerebellar localization is the source's own
      inference from the perceptual thresholds ("likely implies"), not a direct
      observation of cerebellar function.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The role of cerebellar and vestibulo-cerebellar networks is also significant."
    explanation: >-
      The source's own statement that these networks are a substantive part of
      vestibular migraine pathophysiology, supporting curation of this node at
      all rather than folding it into the thalamo-cortical node above.
  downstream:
  - target: Vertigo
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Failure of cerebellar canal-otolith synthesis contributes to the vestibular
      symptoms of an attack through the same convergence sites at which
      trigeminal and vestibular signals interact. Reversibility of this arm is
      what vestibular rehabilitation is thought to exploit.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "this interaction may trigger vestibular symptoms in migraine episodes"
      explanation: >-
        The source states the vestibular-trigeminal interaction at these sites
        may trigger the vestibular symptoms, which is the strength at which this
        edge is asserted - hence an indirect rather than a direct causal claim.
- name: Vestibular CGRP Signaling
  description: >-
    CGRP is expressed in trigeminal terminals innervating the inner ear,
    vestibular nuclei, and vestibulo-cerebellar networks. CGRP release during
    migraine attacks increases excitability and sensitivity in central vestibular
    pathways (via PKC/ERK/CREB activation) and modulates peripheral inner ear
    electrophysiology. This dual-level CGRP signaling (peripheral and central)
    is the mechanistic basis for CGRP-targeted therapy efficacy in vestibular
    migraine.
  biological_processes:
  - preferred_term: Vestibular CGRP receptor signaling
    term:
      id: GO:1990408
      label: calcitonin gene-related peptide receptor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trigeminal innervation and CGRP expression in inner ear structures are interpreted as a biological bridge between migraine biology and otologic/vestibular symptoms."
    explanation: >-
      Establishes CGRP as the biological bridge linking trigeminovascular
      activation to vestibular symptoms through CGRP expression in trigeminal
      terminals and inner ear structures.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Following repeated migraine triggers, CGRP levels and CGRP receptor components (calcitonin receptor-like receptor and receptor activity-modifying protein 1) are upregulated in the vestibular nuclei, and in animal models, local CGRP inhibition or CGRP receptor antagonism reduces c-fos activation and vestibular dysfunction."
    explanation: >-
      Shows that chronic migraine upregulates CGRP signaling in vestibular
      nuclei and that blocking CGRP reduces vestibular nucleus activation and
      behavioral vestibular dysfunction.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "CGRP1 receptor activity in the vestibular nucleus activates the PKC/ERK/CREB pathways and alters synaptic transmission"
    explanation: >-
      Delineates the intracellular cascade (PKC/ERK/CREB) downstream of vestibular
      CGRP1 receptor activation as a mechanism of central sensitization in
      vestibular migraine.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Systemic CGRP administration alters the electrophysiological potentials of the semicircular canals and vestibular end organs and leads to behavioral phonophobia and postural instability in rodents; this indicates that there is a site of action in peripheral end organs in addition to central effects."
    explanation: >-
      Shows that CGRP has direct peripheral effects on vestibular end organs,
      supporting both central and peripheral sites of CGRP action in vestibular
      migraine.
  downstream:
  - target: Trigemino-Vestibular Pathway
    causal_link_type: DIRECT
    description: >-
      CGRP released from activated trigeminal terminals drives sensitization
      of vestibular nuclei through peripheral and central mechanisms, amplifying
      trigemino-vestibular interactions and central vestibular dysfunction.
    evidence:
    - reference: PMID:42643076
      reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and Treatment Approaches."
      supports: SUPPORT
      snippet: "The ability of CGRP-targeted therapies to improve VM symptoms indirectly supports the clinical significance of these pathways."
      explanation: >-
        Clinical efficacy of CGRP monoclonal antibodies (galcanezumab) in
        reducing vestibular migraine disability and dizziness days validates
        CGRP as a key node in vestibular migraine pathophysiology.
- name: PACAP Pathway
  biological_scale: MOLECULAR
  description: >
    Pituitary adenylate cyclase-activating peptide (PACAP) is expressed in
    migraine-related regions including the hypothalamus, pons, thalamus,
    trigeminal ganglia and trigeminal nucleus caudalis, and operates at least
    partly in parallel to CGRP in trigeminovascular nociceptive signaling.
    PACAP infusion provokes migraine attacks in susceptible individuals, and
    the pathway is a target for preventive therapy.
  biological_processes:
  - preferred_term: neuropeptide signaling pathway
    term:
      id: GO:0007218
      label: neuropeptide signaling pathway
  evidence:
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Pituitary adenylate cyclase-activating polypeptide (PACAP) is another important neuropeptide within the trigeminovascular network and, like CGRP, can provoke migraine in susceptible individuals"
    explanation: >
      PACAP provokes migraine attacks in humans, establishing it as a major
      effector neuropeptide alongside CGRP in migraine pathophysiology.
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Mechanistically, PACAP is highly relevant to migraine biology because it is expressed in migraine‐related regions including the hypothalamus, pons, thalamus, trigeminal ganglia, and trigeminal nucleus caudalis, and PACAP infusion can provoke migraine attacks in susceptible individuals"
    explanation: >
      Sources the expression distribution recorded in this node's description,
      which is an expression statement rather than a claim about release from
      trigeminal neurons specifically.
  - reference: DOI:10.1186/s10194-024-01830-2
    reference_title: "VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and carotid artery dilatation induced by PACAP38 in a migraine relevant mouse model"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "This study assessed all three PACAP receptors in a migraine mouse model and suggests a significant role of VPAC receptors in migraine pathophysiology."
    explanation: >
      Receptor-level resolution of the pathway: knockout work in a migraine
      mouse model attributes PACAP38-induced hypersensitivity and carotid
      dilatation to VPAC1/VPAC2 rather than to PAC1, which is the mechanistic
      reason ligand-directed therapy outperformed PAC1 blockade.
  downstream:
  - target: Central Sensitization
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      PACAP released during the headache phase contributes to nociceptive
      transmission within the trigeminovascular system, alongside CGRP, and so
      feeds the sensitization that maintains the attack.
    evidence:
    - reference: PMID:42676555
      reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "During this phase, release of neuropeptides, particularly CGRP and also PACAP, contributes to nociceptive transmission, vascular and neuroimmune signaling, and amplification of headache‐related symptoms"
      explanation: >
        Names PACAP release as a contributor to nociceptive transmission and
        symptom amplification during the headache phase, which is the
        sensitization this edge asserts.
    - reference: PMID:42676555
      reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "SGCs and Schwann cells are well positioned to respond to ATP, CGRP, substance P, PACAP, and inflammatory mediators, thereby reinforcing peripheral sensitization"
      explanation: >
        Identifies peripheral glial responsiveness to PACAP as a route
        reinforcing sensitization.
phenotypes:
- name: Headache
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Unilateral, pulsating, moderate-severe
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:37495957
    reference_title: "Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice."
    supports: SUPPORT
    snippet: "In both WT and FHM1 mutant mice, CSDs induced headache-related behaviour,
      as evidenced by increased MGS scores and the occurrence of oculotemporal strokes,
      at 30 min."
    explanation: Demonstrates that cortical spreading depression directly
      induces headache-related behaviors in animal models.
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "We propose that neuronal stress induced by CSD or synaptic activity-energy
      mismatch may initiate a parenchymal inflammatory signaling cascade, transmitted
      to the meninges, thereby triggering lasting headaches characteristic of migraine,
      with or without aura."
    explanation: Explains the mechanistic pathway from neuronal stress to the
      characteristic lasting headaches of migraine.
- name: Photophobia
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:35322292
    reference_title: "Photophobia in headache disorders: characteristics and potential mechanisms."
    supports: SUPPORT
    snippet: "The coexistence of photophobia and headache is associated with the interactions
      between visual and pain pathway at retina, midbrain, thalamus, hypothalamus
      and visual cortex."
    explanation: Describes the neuroanatomical basis for photophobia in migraine
      through visual-pain pathway interactions.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Intracerebroventricular injection of CGRP induces aversion to bright
      or dim light in transgenic mice that overexpress the human RAMP1 subunit of
      the CGRP receptor"
    explanation: CGRP induces light-aversive (photophobia-like) behavior in a mouse
      model overexpressing the human CGRP-receptor RAMP1 subunit, and olcegepant blocks
      it, mechanistically linking CGRP signaling to migraine photophobia.
- name: Phonophobia
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Phonophobia
    term:
      id: HP:0002183
      label: Phonophobia
  evidence:
  - reference: PMID:33305448
    reference_title: "Phonophobia and brainstem excitability in migraine."
    supports: SUPPORT
    snippet: "Higher amplitudes of BAEP waves in migraineurs and their relationship
      with the frequency of headache and HT suggest the sensitization of brainstem
      auditory neurons."
    explanation: Demonstrates that phonophobia in migraine is associated with
      sensitization of brainstem auditory neurons, as evidenced by higher
      brainstem auditory evoked potential amplitudes.
- name: Nausea
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "may be accompanied by associated symptoms of photophobia, phonophobia,
      osmophobia, allodynia, pain on movement, and nausea and vomiting."
    explanation: Nausea and vomiting are established associated symptoms of the
      migraine headache phase.
- name: Visual Aura
  category: Neurological
  frequency: OCCASIONAL
  notes: Scintillating scotoma, fortification spectra
  phenotype_term:
    preferred_term: Visual aura (scintillating scotoma)
    term:
      id: HP:0010822
      label: Scintillating scotoma
  evidence:
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "PET studies utilizing inflammation markers have revealed meningeal inflammatory
      activity in patients experiencing migraine with aura, particularly over the
      occipital cortex generating visual auras."
    explanation: Demonstrates that visual auras in migraine are associated with
      inflammatory activity localized to the occipital cortex, the brain region
      responsible for visual processing.
- name: Vertigo
  category: Neurological
  frequency: OCCASIONAL
  notes: Vestibular migraine - spontaneous, positional, visually-induced, or head-motion-induced
  phenotype_term:
    preferred_term: Vertigo
    term:
      id: HP:0002321
      label: Vertigo
  evidence:
  - reference: PMID:38619053
    reference_title: "Vestibular migraine: an update."
    supports: SUPPORT
    snippet: "Vestibular migraine is an underdiagnosed migraine phenotype that shares
      the pathophysiological mechanisms of migraine, with growing interest in recent
      years."
    explanation: Establishes vestibular migraine as a recognized migraine
      phenotype where vertigo is a prominent symptom.
  - reference: PMID:37889468
    reference_title: "Vestibular Migraine Pathophysiology and Treatment: a Narrative Review."
    supports: SUPPORT
    snippet: "There is evidence of abnormal sensory processing and integration in
      VM patients. Calcitonin gene-related peptide (CGRP) has also been found to play
      a role in trigeminal and vestibular nucleus pathways."
    explanation: Links vestibular symptoms to abnormal sensory processing and
      CGRP signaling in vestibular pathways.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative
      Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and
      Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evidence suggests that attacks are primarily caused by abnormal central
      processing and integration of vestibular, visual, and nociceptive inputs, rather
      than by entirely peripheral labyrinthine insufficiency. Studies have identified
      impairments in canal-otolith integration, alterations in vestibulo-ocular responses,
      and dysfunction in the vestibulo-thalamocortical and cerebellar networks that
      process multisensory vestibular signals."
    explanation: Identifies central multisensory dysfunction in vestibulo-thalamic-cortical
      and cerebellar networks as the primary mechanism of vertigo in VM, rather than
      peripheral vestibular pathology alone.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative
      Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and
      Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central sensitization is an increasingly important mechanism in VM.
      Phenotypes associated with widespread cutaneous allodynia, sleep disturbances,
      tinnitus, depressive symptoms, and high disability can be interpreted as clinical
      manifestations of increased sensitivity in thalamocortical sensory processing."
    explanation: Central sensitization of thalamic and cortical sensory networks
      contributes to vertigo and associated multisensory symptoms in VM.
  - reference: PMID:42643076
    reference_title: "Vestibular Migraine: A Systematic Literature Search and Narrative
      Review of Diagnostic Criteria, Pathophysiology, Differential Diagnosis, and
      Treatment Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The role of cerebellar and vestibulo-cerebellar networks is also significant.
      Studies showing changes in cerebellar functional activity following vestibular
      rehabilitation support the possibility of treatment-induced compensation and
      neuroplasticity."
    explanation: Cerebellar compensation and plastic changes in vestibulo-cerebellar
      networks contribute to vertigo pathogenesis and can be modulated through vestibular
      rehabilitation.
- name: Cutaneous Allodynia
  category: Neurological
  frequency: FREQUENT
  notes: Periorbital and, with progression, extracephalic; a clinical marker of
    central sensitization during attacks
  phenotype_term:
    preferred_term: Cutaneous allodynia
    term:
      id: HP:0012533
      label: Allodynia
  evidence:
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As the migraine attack progresses, cutaneous allodynia develops in the
      periorbital area, signaling central sensitization of convergent TNC neurons and
      an increased resistance to the efficacy of triptans."
    explanation: Cutaneous allodynia is a recognized migraine phenotype that develops
      as attacks progress, reflecting central sensitization of trigeminal nucleus
      caudalis neurons and predicting reduced triptan efficacy.
  - reference: PMID:18427069
    reference_title: "Prevalence and characteristics of allodynia in headache sufferers: a population study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence was significantly higher in transformed migraine (TM, 68.3%)
      than in episodic migraine (63.2%, p < 0.01)"
    explanation: In the AMPP population study, cutaneous allodynia was present in
      63.2% of episodic migraine and 68.3% of transformed (chronic) migraine
      sufferers, supporting a FREQUENT (30-79%) frequency band.
biochemical:
- name: CGRP
  presence: Elevated
  context: During attacks
  evidence:
  - reference: PMID:37755358
    reference_title: "Migraine: Advances in the Pathogenesis and Treatment."
    supports: SUPPORT
    snippet: "Special emphasis is given to the role of calcitonin gene-related peptide
      (CGRP) in migraine development. CGRP not only contributes to symptoms but also
      represents a promising therapeutic target, with inhibitors showing effectiveness
      in migraine management."
    explanation: Confirms the central role of CGRP in migraine pathophysiology
      and its elevation during attacks.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several studies demonstrated that blood levels of CGRP obtained from
      the jugular vein of people with migraine are elevated during a migraine attack."
    explanation: Jugular venous CGRP is elevated during migraine attacks, directly
      supporting CGRP elevation during the ictal phase.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the interictal levels of CGRP of people with chronic migraine are
      significantly elevated when compared to those of patients with episodic migraine,
      and it was suggested that these elevated interictal CGRP levels in people with
      migraine could be a biomarker aiding the diagnosis of chronic migraine."
    explanation: Interictal CGRP is elevated in chronic versus episodic migraine and
      has been proposed as a diagnostic biomarker of chronic migraine.
- name: Serotonin
  presence: Decreased
  context: May contribute to attacks
  evidence:
  - reference: PMID:17970989
    reference_title: "Serotonin and migraine: biology and clinical implications."
    supports: SUPPORT
    snippet: "Amongst the many neurotransmitters in the brain, the serotonergic (serotonin,
      5-HT) system from the brainstem raphe nucleus has been most convincingly implicated
      in migraine pathophysiology."
    explanation: Serotonergic system is the most convincingly implicated
      neurotransmitter system in migraine.
  - reference: PMID:17970989
    reference_title: "Serotonin and migraine: biology and clinical implications."
    supports: SUPPORT
    snippet: "The documented changes in 5-HT metabolism and in the processing of central
      5-HT-mediated responses during and in between migraine attacks have led to the
      suggestion that migraine is a consequence of a central neurochemical imbalance
      that involves a low serotonergic disposition."
    explanation: Low serotonin disposition is associated with migraine
      susceptibility and attacks.
genetic:
- name: CACNA1A
  gene_term:
    preferred_term: CACNA1A
    term:
      id: hgnc:1388
      label: CACNA1A
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: Familial hemiplegic migraine
  evidence:
  - reference: PMID:32430436
    reference_title: "Diagnostic and therapeutic aspects of hemiplegic migraine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion
      transport are implicated.
    explanation: CACNA1A encodes the Cav2.1 P/Q-type voltage-gated calcium channel alpha-1A subunit; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM1 locus.
  - reference: PMID:38508838
    reference_title: "Genetics of migraine: complexity, implications, and potential clinical applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Some distinct, rare, familial migraine subtypes are caused by pathogenic
      variants in genes involved in ion transport and neurotransmitter release, suggesting
      an underlying vulnerability of the excitatory-inhibitory balance in the brain"
    explanation: Establishes that rare familial migraine subtypes arise from
      pathogenic variants in ion-transport genes; the source does not name the
      individual genes, so support is PARTIAL.
- name: ATP1A2
  gene_term:
    preferred_term: ATP1A2
    term:
      id: hgnc:800
      label: ATP1A2
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: Familial hemiplegic migraine
  evidence:
  - reference: PMID:32430436
    reference_title: "Diagnostic and therapeutic aspects of hemiplegic migraine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion
      transport are implicated.
    explanation: ATP1A2 encodes the alpha-2 subunit of the Na+/K+-ATPase; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM2 locus.
  - reference: PMID:38508838
    reference_title: "Genetics of migraine: complexity, implications, and potential clinical applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Some distinct, rare, familial migraine subtypes are caused by pathogenic
      variants in genes involved in ion transport and neurotransmitter release, suggesting
      an underlying vulnerability of the excitatory-inhibitory balance in the brain"
    explanation: Establishes that rare familial migraine subtypes arise from
      pathogenic variants in ion-transport genes; the source does not name the
      individual genes, so support is PARTIAL.
- name: SCN1A
  gene_term:
    preferred_term: SCN1A
    term:
      id: hgnc:10585
      label: SCN1A
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: Familial hemiplegic migraine
  evidence:
  - reference: PMID:32430436
    reference_title: "Diagnostic and therapeutic aspects of hemiplegic migraine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in CACNA1A, ATP1A2 and SCN1A encoding proteins involved in ion
      transport are implicated.
    explanation: SCN1A encodes the Nav1.1 voltage-gated sodium channel; it is one of the three ion-transport genes named as implicated in hemiplegic migraine, and is the FHM3 locus.
  - reference: PMID:38508838
    reference_title: "Genetics of migraine: complexity, implications, and potential clinical applications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Some distinct, rare, familial migraine subtypes are caused by pathogenic
      variants in genes involved in ion transport and neurotransmitter release, suggesting
      an underlying vulnerability of the excitatory-inhibitory balance in the brain"
    explanation: Establishes that rare familial migraine subtypes arise from
      pathogenic variants in ion-transport genes; the source does not name the
      individual genes, so support is PARTIAL.
- name: TRPM8
  gene_term:
    preferred_term: TRPM8
    term:
      id: hgnc:17961
      label: TRPM8
  association: Risk Factor
  relationship_type: RISK_FACTOR
  evidence:
  - reference: PMID:21666692
    reference_title: "Genome-wide association study reveals three susceptibility loci for common migraine in the general population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113
      (12q13.3, LRP1) were among the top seven associations (P < 5 × 10(-6)) with
      migraine."
    explanation: GWAS identifies rs10166942 near TRPM8 as a genome-wide-significant
      migraine susceptibility locus, which is the risk-factor claim.
  - reference: PMID:31873179
    reference_title: "Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TRPM8 is highly expressed in migraine and pain neuronal circuitry, such
      as trigeminal and dorsal root ganglia"
    explanation: Supports TRPM8 expression in trigeminal and dorsal root ganglion
      pain circuitry, providing a mechanism for the GWAS association; the snippet
      itself addresses expression rather than risk.
- name: LRP1
  gene_term:
    preferred_term: LRP1
    term:
      id: hgnc:6692
      label: LRP1
  association: Risk Factor
  relationship_type: RISK_FACTOR
  evidence:
  - reference: PMID:21666692
    reference_title: "Genome-wide association study reveals three susceptibility loci for common migraine in the general population."
    supports: SUPPORT
    snippet: "rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113
      (12q13.3, LRP1) were among the top seven associations (P < 5 × 10(-6)) with
      migraine."
    explanation: GWAS of 5,122 migraineurs identified LRP1 SNP rs11172113 as
      genome-wide significant for migraine susceptibility.
  - reference: PMID:21666692
    reference_title: "Genome-wide association study reveals three susceptibility loci for common migraine in the general population."
    supports: SUPPORT
    snippet: "LRP1 modulates neuronal glutamate signaling, plausibly linking both
      genes to migraine pathophysiology."
    explanation: LRP1's role in neuronal glutamate signaling provides
      mechanistic link to migraine.
environmental:
- name: Stress
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Common trigger
  evidence:
  - reference: PMID:35143379
    reference_title: "Cognitive or daily stress association with headache and pain induction in migraine and tension-type headache patients: a systematic review."
    supports: SUPPORT
    snippet: "Both mental/cognitive stress and daily stress (perceived) were related
      to an increase in pain perception and related to the development of headache
      or enhanced transient pain intensity in migraine and TTH patients."
    explanation: Systematic review confirms stress as a trigger for migraine
      headaches.
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "In both MA and MO the most conspicuous precipitating factor was stress
      and mental tension."
    explanation: Epidemiological study identifies stress as the most common
      precipitating factor for both migraine subtypes.
- name: Sleep Disturbance
  exposure_term:
    preferred_term: disturbed sleep
    term:
      id: XCO:0001068
      label: sleep
  notes: >-
    Both insufficient and excessive sleep are commonly reported migraine
    triggers; disrupted sleep-wake regulation is one of the recognised
    precipitating factors for attacks.
  evidence:
  - reference: PMID:28436283
    reference_title: "Trigger Factors in Childhood Migraine: A Prospective Clinic-Based Study From North of France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lack of sleep (51.4%), stress (44.6%), warm climate (41.9%), noise (32.4%), and excitation (29.7%) were the most frequently reported"
    explanation: "Prospective 3-month trigger diary in 101 paediatric migraine patients; lack of sleep was the single most frequently reported trigger. PARTIAL because it evidences insufficient sleep only, not the excessive-sleep half of this annotation, and the cohort is paediatric."
- name: Hormonal Changes
  notes: Menstruation, oral contraceptives
  evidence:
  - reference: PMID:19076658
    reference_title: "Epidemiology and biology of menstrual migraine."
    supports: SUPPORT
    snippet: "The trigger thought to be partially responsible for menstrually associated
      migraine is a significant drop in circulating estrogen that is noted during
      2-3 days prior to onset of menses."
    explanation: Estrogen withdrawal is established as the hormonal trigger for
      menstrual migraine.
  - reference: PMID:19076658
    reference_title: "Epidemiology and biology of menstrual migraine."
    supports: SUPPORT
    snippet: "It is estimated that approximately 50% of women have an increased risk
      of experiencing migraine during the premenstrual phase of decreasing estrogen
      levels."
    explanation: Half of female migraineurs have increased risk during
      premenstrual estrogen decline.
  - reference: PMID:1525797
    reference_title: "Migraine with aura and migraine without aura: an epidemiological study."
    supports: SUPPORT
    snippet: "Onset at menarche, menstrual precipitation, menstrual problems, influence
      of pregnancy and use of oral contraceptives all showed some relationship with
      the presence of MO and less with MA."
    explanation: Population study confirms hormonal factors including
      menstruation and oral contraceptives as migraine triggers.
- name: Dietary Triggers
  notes: Caffeine withdrawal and alcohol have provocation-study support; chocolate
    and aged cheese are commonly cited but poorly supported
  evidence:
  - reference: PMID:27699780
    reference_title: "Diet and Headache: Part 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Caffeine withdrawal and administration of MSG (dissolved in liquid) has the strongest evidence for triggering attacks of headache as evidenced by multiple positive provocation studies"
    explanation: "Narrative review grading the evidence per food. Caffeine withdrawal is the best-supported dietary trigger, resting on positive provocation studies rather than patient self-report."
  - reference: PMID:15806385
    reference_title: "[Alimentary trigger factors that provoke migraine and tension-type headache]."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "the importance of chocolate has been doubted seriously, and scientific evidence for cheese as a precipitating factor is lacking"
    explanation: "Refutes two of the four items the note previously listed. The note has been rewritten accordingly: alcohol and caffeine withdrawal are retained as controlled-trial-supported precipitants, while chocolate and aged cheese are marked as commonly cited but poorly supported. This is the same correction pattern as Celiac early-gluten-introduction in tranche 1."
  influences_mechanisms:
  - target: Headache
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Caffeine withdrawal and monosodium glutamate provoke migraine attacks in controlled provocation studies.
    evidence:
    - reference: PMID:27699780
      reference_title: "Diet and Headache: Part 1."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: Caffeine withdrawal and administration of MSG (dissolved in liquid) has the strongest evidence for triggering attacks of headache as evidenced by multiple positive provocation studies
      explanation: 'Provocation studies are experimental rather than self-reported, which is what makes this a trigger claim rather than an association. The edge jumps the cortical-spreading-depression and trigeminovascular nodes through which a provoked attack proceeds. Scoped to caffeine withdrawal and MSG: the entry''s own REFUTE item withdraws chocolate and aged cheese.'
- name: Weather Changes
  exposure_term:
    preferred_term: weather change exposure
    term:
      id: ECTO:1000020
      label: exposure to weather
  notes: Barometric pressure changes
  evidence:
  - reference: PMID:36853848
    reference_title: "Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross-sectional study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we found that low barometric pressure, barometric pressure changes, higher humidity, and rainfall were associated with an increased number of headache occurrences"
    explanation: "Smartphone-diary study of 336,951 hourly headache events, which is the scale this question has historically lacked -- the paper's own background notes the weather-headache relationship remained unknown. PARTIAL because the outcome is headache occurrence across a mixed cohort (37.2% physician-diagnosed migraine) rather than migraine attacks specifically."
- name: Sensory Stimuli
  notes: Noise is the sensory trigger with prospective diary support; bright lights
    and strong odours are commonly cited but not evidenced here
  evidence:
  - reference: PMID:28436283
    reference_title: "Trigger Factors in Childhood Migraine: A Prospective Clinic-Based Study From North of France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lack of sleep (51.4%), stress (44.6%), warm climate (41.9%), noise (32.4%), and excitation (29.7%) were the most frequently reported"
    explanation: "Prospective trigger diary in which noise was reported before a third of attacks, establishing sensory stimuli as a precipitant. PARTIAL because the diary evidences noise only; the bright lights and strong odours also named on this exposure are unevidenced here, and a light/odour-specific source was searched for and not found."
treatments:
- name: Triptans
  description: First-line acute treatment (sumatriptan, rizatriptan).
  evidence:
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin
      gene-related peptide antibodies and triptans in treating migraine attacks, both
      with and without aura, supports the concept of migraine pain originating in
      meninges."
    explanation: Clinical efficacy of triptans in treating migraine attacks
      validates their role as first-line acute treatment.
  - reference: PMID:30982963
    reference_title: "CGRP and the Trigeminal System in Migraine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sumatriptan inhibits release of CGRP from trigeminal nerve terminals
      and in that study, produced parallel reductions in migraine headache pain
      intensity and blood levels of CGRP."
    explanation: Sumatriptan reduces migraine pain in parallel with reduced blood
      CGRP, supporting inhibition of trigeminal CGRP release as a triptan mechanism
      of action.
- name: NSAIDs
  description: Effective for mild-moderate attacks.
  evidence:
  - reference: PMID:27713337
    reference_title: "NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data."
    supports: SUPPORT
    snippet: "NSAIDs remain the most commonly used therapies for the migraine attack.
      This is in part due to their wide availability as over-the-counter drugs and
      their pharmaco-economic advantages, but also to a favorable efficacy/side effect
      profile at least in attacks of mild and moderate intensity."
    explanation: NSAIDs are widely used for migraine attacks due to their
      favorable efficacy and side effect profile, particularly for mild to
      moderate attacks.
- name: CGRP Antagonists (Gepants)
  description: Acute treatment option (ubrogepant, rimegepant).
  evidence:
  - reference: PMID:37755358
    reference_title: "Migraine: Advances in the Pathogenesis and Treatment."
    supports: SUPPORT
    snippet: "CGRP not only contributes to symptoms but also represents a promising
      therapeutic target, with inhibitors showing effectiveness in migraine management."
    explanation: CGRP antagonists (gepants) are a class of CGRP inhibitors that
      have demonstrated effectiveness in migraine management.
  - reference: PMID:34160823
    reference_title: "The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Newly introduced acute treatments include two small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant, rimegepant); a serotonin (5-HT1F ) agonist (lasmiditan)"
    explanation: The American Headache Society consensus statement integrates the small-molecule CGRP receptor antagonists (gepants) ubrogepant and rimegepant into acute migraine care.
- name: Ditans (Lasmiditan)
  description: Acute treatment option (lasmiditan, a selective 5-HT1F agonist).
  therapeutic_modality: SMALL_MOLECULE
  notes: >-
    Dizziness and somnolence are common and postdose driving restrictions limit routine
    use in some patients, which is the reason the cited review positions lasmiditan as
    an option after triptans rather than alongside them.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lasmiditan
      term:
        id: CHEBI:755069
        label: lasmiditan
  target_mechanisms:
  - target: Trigeminovascular Activation
    treatment_effect: INHIBITS
    description: >-
      5-HT1F agonism dampens trigeminal transmission centrally. Unlike the triptans,
      lasmiditan aborts attacks without constricting cranial vessels.
    evidence:
    - reference: PMID:42676555
      reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "Its efficacy supports the concept that central trigeminal modulation can abort attacks independently of vascular mechanisms."
      explanation: >-
        The review reads lasmiditan's clinical efficacy as evidence that the drug acts on
        the trigeminal pathway itself. Indirect: therapeutic response is cited as
        validation of the mechanism it targets, not as a direct measurement of it.
  evidence:
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Lasmiditan, a selective 5‐HT1F agonist, is another migraine‐specific acute therapy that does not cause vasoconstriction"
    explanation: >-
      States the pharmacological class and the nonvasoconstrictive property that
      distinguish ditans from triptans, which is what this treatment entry describes.
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Thus, lasmiditan is best positioned as an option for patients in whom triptans are unsuitable or ineffective."
    explanation: >-
      The review authors' placement of lasmiditan in the acute-treatment sequence. This is
      their recommendation rather than a reported clinical result, so it is graded OTHER,
      matching how the sibling gepant entry grades the equivalent AHS positioning statement.
- name: Beta Blockers
  description: Preventive therapy (propranolol, metoprolol).
  evidence:
  - reference: PMID:30893319
    reference_title: "Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "Compared to placebo, propranolol reduced episodic migraine headaches
      by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely
      to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7)."
    explanation: Meta-analysis of 108 RCTs confirms propranolol efficacy for
      migraine prevention with high-quality evidence.
  - reference: PMID:30893319
    reference_title: "Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "There is high quality evidence that propranolol is better than placebo
      for episodic migraine headache."
    explanation: Systematic review establishes beta-blockers as effective
      first-line preventive therapy.
- name: Topiramate
  description: Preventive therapy.
  evidence:
  - reference: PMID:24494792
    reference_title: "Efficacy and mechanism of anticonvulsant drugs in migraine."
    supports: SUPPORT
    snippet: "Efficacy has been demonstrated in randomized placebo-controlled trials
      for topiramate and valproic acid including divalproex sodium."
    explanation: Clinical trials have established the efficacy of topiramate for
      migraine prevention.
  - reference: PMID:24494792
    reference_title: "Efficacy and mechanism of anticonvulsant drugs in migraine."
    supports: SUPPORT
    snippet: "Effective anticonvulsants, such as topiramate and valproate, target
      nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms
      involved in cortical spreading depression."
    explanation: Explains the mechanism by which topiramate prevents migraine
      through effects on trigeminovascular pathways and cortical spreading
      depression.
- name: Valproate
  description: Preventive therapy.
  evidence:
  - reference: PMID:24494792
    reference_title: "Efficacy and mechanism of anticonvulsant drugs in migraine."
    supports: SUPPORT
    snippet: "Efficacy has been demonstrated in randomized placebo-controlled trials
      for topiramate and valproic acid including divalproex sodium."
    explanation: Clinical trials have established the efficacy of
      valproate/valproic acid for migraine prevention.
  - reference: PMID:24494792
    reference_title: "Efficacy and mechanism of anticonvulsant drugs in migraine."
    supports: SUPPORT
    snippet: "Effective anticonvulsants, such as topiramate and valproate, target
      nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms
      involved in cortical spreading depression."
    explanation: Explains the mechanism by which valproate prevents migraine
      through effects on trigeminovascular pathways and cortical spreading
      depression.
- name: CGRP Monoclonal Antibodies
  description: Preventive therapy (erenumab, fremanezumab, galcanezumab).
  evidence:
  - reference: PMID:39080518
    reference_title: "Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache."
    supports: SUPPORT
    snippet: "The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin
      gene-related peptide antibodies and triptans in treating migraine attacks, both
      with and without aura, supports the concept of migraine pain originating in
      meninges."
    explanation: Anti-CGRP monoclonal antibodies have demonstrated clinical
      efficacy in treating migraine, supporting their use as preventive therapy.
  - reference: PMID:37755358
    reference_title: "Migraine: Advances in the Pathogenesis and Treatment."
    supports: SUPPORT
    snippet: "CGRP not only contributes to symptoms but also represents a promising
      therapeutic target, with inhibitors showing effectiveness in migraine management."
    explanation: CGRP monoclonal antibodies are CGRP inhibitors that target this
      key migraine pathway.
  - reference: PMID:34160823
    reference_title: "The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "New preventive treatments include an intravenous anti-CGRP ligand monoclonal antibody (eptinezumab)."
    explanation: The American Headache Society consensus statement adds the intravenous anti-CGRP monoclonal antibody eptinezumab to migraine preventive options.
- name: Anti-PACAP Ligand Monoclonal Antibody
  description: >-
    Investigational preventive therapy directed at the PACAP ligand
    (Lu AG09222), the most advanced non-CGRP neuropeptide class. Phase 2 only;
    not an approved treatment.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  notes: >-
    Ligand-directed rather than receptor-directed on purpose: a monoclonal
    antibody against the PAC1 receptor failed clinically, which is consistent
    with the knockout evidence attributing PACAP38-induced hypersensitivity to
    VPAC1/VPAC2 rather than PAC1.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: monoclonal antibody
      term:
        id: NCIT:C20401
        label: Monoclonal Antibody
  target_mechanisms:
  - target: PACAP Pathway
    treatment_effect: INHIBITS
    description: >-
      Sequestering the PACAP ligand blocks the pathway upstream of all three
      PACAP receptors, which is the join point between this treatment and the
      PACAP mechanism node.
    evidence:
    - reference: PMID:42676555
      reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "Ligand‐directed approaches now appear more promising than receptor‐selective blockade, since a monoclonal antibody against the PAC1 receptor failed clinically, whereas the anti‐PACAP ligand antibody Lu AG09222 showed Phase 2 efficacy in reducing monthly migraine days"
      explanation: >-
        Phase 2 efficacy of ligand sequestration is cited as validation of the
        PACAP pathway it targets. Indirect: therapeutic response stands in for
        a direct measurement of the mechanism.
  evidence:
  - reference: PMID:42676555
    reference_title: "Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "PACAP‐targeted therapies are the most advanced emerging class and provide proof of principle that migraine can be modified through non‐CGRP neuropeptide pathways"
    explanation: >-
      Establishes the class as the leading non-CGRP neuropeptide option, which
      is what this treatment record is for.
- name: Botulinum Toxin
  description: For chronic migraine prevention.
  evidence:
  - reference: PMID:38910144
    reference_title: "Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis."
    supports: SUPPORT
    snippet: "Among all the drugs for the preventive drugs for CM, Botulinum toxin
      A has the best efficacy and safety profile, closely followed by calcitonin gene-related
      peptide (CGRP) monoclonal antibodies (mAbs)."
    explanation: Network meta-analysis of 24 RCTs demonstrates botulinum toxin A
      has the best efficacy and safety profile among chronic migraine preventive
      treatments.
- name: Neuromodulation
  description: Non-invasive devices for prevention and acute treatment.
  evidence:
  - reference: PMID:37755358
    reference_title: "Migraine: Advances in the Pathogenesis and Treatment."
    supports: SUPPORT
    snippet: "Finally, the paper delves into neuromodulation as an innovative treatment
      modality. Clinical studies indicating its effectiveness in migraine management
      are reviewed"
    explanation: Clinical studies have demonstrated the effectiveness of
      neuromodulation devices in migraine management.
clinical_trials:
- name: NCT07040813
  phase: PHASE_III
  status: RECRUITING
  description: A randomized placebo-controlled double-blind trial investigating
    the efficacy of onabotulinumtoxin A (Botox) added to CGRP monoclonal
    antibody therapy for chronic migraine prevention over 12 weeks. The study
    evaluates dual therapy versus CGRP monoclonal antibody monotherapy in
    reducing monthly migraine days.
  target_phenotypes:
  - preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  - preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: clinicaltrials:NCT07040813
    reference_title: "A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine"
    supports: SUPPORT
    snippet: "The study will evaluate the efficacy of onabotulinumtoxin A when added
      to CGRP monoclonal antibody therapy in chronic migraine prevention. Adverse
      events and change in disease activity will be monitored."
    explanation: This Phase III trial directly evaluates a combination approach
      targeting two major migraine pathways (CGRP and acetylcholine) for chronic
      migraine prevention.
- name: NCT06241313
  phase: PHASE_III
  status: RECRUITING
  description: Randomized, double-blind, placebo-controlled, multiple-attack
    study evaluating atogepant (CGRP antagonist/gepant) for acute treatment of
    migraine. The ECLIPSE trial assesses efficacy, safety, tolerability, and
    consistency of effect with an open-label extension phase.
  target_phenotypes:
  - preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  - preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  - preferred_term: Phonophobia
    term:
      id: HP:0002183
      label: Phonophobia
  evidence:
  - reference: clinicaltrials:NCT06241313
    reference_title: "Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)"
    supports: SUPPORT
    snippet: "The main goal of the study is to see if atogepant is effective, safe,
      and well-tolerated in treating migraine attacks quickly."
    explanation: This Phase III trial evaluates atogepant, a CGRP antagonist,
      for acute migraine treatment, providing clinical evidence for
      transitioning this preventive agent to acute attack management.
- name: NCT07061847
  phase: PHASE_II
  status: RECRUITING
  description: Study evaluating bilateral middle meningeal artery (MMA)
    lidocaine infusion as a novel interventional approach for chronic
    debilitating migraines. Investigates localized anesthesia targeting the
    pain-sensitive meningeal tissues implicated in migraine pathophysiology.
  target_phenotypes:
  - preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: clinicaltrials:NCT07061847
    reference_title: "Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines"
    supports: SUPPORT
    snippet: "The main purpose of this study is to evaluate the effectiveness of a
      new treatment in improving chronic migraine symptoms. This treatment involves
      a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors,
      potentially leading to improvements in chronic migraine intensity, frequency,
      and duration."
    explanation: This Phase II trial investigates a novel interventional
      procedure targeting meningeal pain pathways in chronic migraine, providing
      clinical evidence for direct vascular intervention approaches.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE318177
  title: DNA methylation in episodic migraine and medication overuse headache.
  description: These data were generated within the Epimode project - a pilot, longitudinal, prospective, observational study designed to investigate DNA methylation in headache disorders. 20 episodic migraineurs (EM), 25 medication overuse headache patients (MOH) and 13 healthy controls (HC) were enrolled in the study. EM and HC samples were collected at baseline (T0) and ath the follow-up visit 6 months later (T1). MOH samples were collected at baseline (T0), at treatment time point (T1) and at the follow-up visits after 2 (T2) and 6 (T3) months from the therapeutic intervention.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METHYLATION
  sample_count: 142
  publication: PMID:41721229
  notes: Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE197289
  title: Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine
  description: The sensitization of trigeminal ganglion neurons contributes to primary headache disorders such as migraine, but the specific neuronal and non-neuronal trigeminal subtypes involved remain unclear. We thus developed a cell atlas in which human and mouse trigeminal ganglia are transcriptionally and epigenomically profiled at single-cell resolution. These data describe evolutionarily conserved and human-specific gene expression patterns within each trigeminal ganglion cell type, as well as the transcription factors and gene regulatory elements that contribute to cell-type-specific gene expression.
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 36
  publication: PMID:35349784
  notes: Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. GEO reports both Homo sapiens and Mus musculus; structured organism is omitted because Dataset.organism is single-valued.
- accession: geo:GSE269117
  title: Multiomic-based Immune Response Profiling in Migraine, Vestibular Migraine and Meniere's Disease
  description: We analysed the immune profile of individuals with MI, VM, and MD using scRNAseq and scATACseq in PBMCs and to determine active biochemical pathways to identify new potential druggable molecular targets
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MULTI_OMICS
  sample_count: 24
  publication: PMID:39294737
  notes: Identified by GEO DataSets index search for Migraine (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001006795
  title: RNA sequencing of spontaneous migraine attacks
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Migraine"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
references:
- reference: DOI:10.1016/j.heliyon.2023.e14786
  title: 'Primary headache disorders: From pathophysiology to neurostimulation therapies'
  findings: []
- reference: DOI:10.1186/s10194-023-01628-8
  title: Optogenetic cortical spreading depolarization induces headache-related
    behaviour and neuroinflammatory responses some prolonged in familial
    hemiplegic migraine type 1 mice
  findings: []
- reference: DOI:10.1186/s10194-024-01741-2
  title: The glymphatic system in migraine and other headaches
  findings: []
- reference: DOI:10.1186/s10194-024-01827-x
  title: Unraveling the interplay of neuroinflammatory signaling between
    parenchymal and meningeal cells in migraine headache
  findings: []
- reference: DOI:10.1186/s10194-024-01830-2
  title: VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and
    carotid artery dilatation induced by PACAP38 in a migraine relevant mouse
    model
  findings: []
- reference: DOI:10.1523/jneurosci.0368-23.2023
  title: Meningeal P2X7 Signaling Mediates Migraine-Related Intracranial
    Mechanical Hypersensitivity
  findings: []
- reference: DOI:10.3389/fneur.2024.1307319
  title: 'A role of NLRP3 and MMP9 in migraine progression: a systematic review of
    translational study'
  findings: []
- reference: DOI:10.3390/ijms241512268
  title: 'Migraine Treatment: Towards New Pharmacological Targets'
  findings: []
- reference: DOI:10.3390/jcm13092701
  title: The Dawn and Advancement of the Knowledge of the Genetics of Migraine
  findings: []
- reference: DOI:10.3390/molecules29143385
  title: The TRPA1 Ion Channel Mediates Oxidative Stress-Related Migraine
    Pathogenesis
  findings: []
- reference: DOI:10.3390/neurolint15030067
  title: 'Migraine: Advances in the Pathogenesis and Treatment'
  findings: []
discussions:
- discussion_id: gap_migraine_episodic_to_chronic_chronification
  prompt: >-
    What molecular and circuit-level mechanisms drive the transition from episodic
    migraine (fewer than 15 headache days/month) to chronic migraine (15 or more
    days/month), and does the CGRP-driven shift from activity-dependent to
    activity-independent central sensitization account for chronification?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Central Sensitization
  - pathophysiology#CGRP Pathway
  rationale: >-
    PMID:30982963 proposes that a shift in central sensitization from
    activity-dependent (triggered only during attacks) to activity-independent
    (present interictally) may be the key mechanism of chronification. However,
    the upstream triggers of this shift — cumulative microglial sensitization,
    medication overuse, repeated CSD episodes, or genetic predisposition —
    remain unclear. Understanding this transition is clinically critical because
    it defines who progresses from episodic to chronic migraine and informs
    preventive treatment selection.
- discussion_id: gap_migraine_mwoa_premonitory_initiation
  prompt: >-
    In migraine without aura, does premonitory hypothalamic/brainstem activation
    directly gate the trigeminovascular pathway without cortical spreading
    depression, and which neuroimaging markers can distinguish this brainstem-initiated
    pathway from the CSD-initiated aura pathway?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cortical Spreading Depression
  - pathophysiology#Trigeminovascular Activation
  rationale: >-
    The mechanistic_hypotheses block encodes two initiation routes for migraine:
    CSD-initiated (canonical for MwA) and brainstem/hypothalamic-initiated
    (emerging model for MwoA). The brainstem-initiation route is supported by
    premonitory symptom timing and functional MRI studies showing hypothalamic
    activation before headache onset, but direct causal evidence that
    hypothalamic circuits gate trigeminovascular activation independent of CSD
    is lacking. Differentiating these pathways has implications for subtype-specific
    preventive therapies.
📚

References & Deep Research

References

11
DOI:10.1016/j.heliyon.2023.e14786
Primary headache disorders: From pathophysiology to neurostimulation therapies
No top-level findings curated for this source.
DOI:10.1186/s10194-023-01628-8
Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice
No top-level findings curated for this source.
DOI:10.1186/s10194-024-01741-2
The glymphatic system in migraine and other headaches
No top-level findings curated for this source.
DOI:10.1186/s10194-024-01827-x
Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache
No top-level findings curated for this source.
DOI:10.1186/s10194-024-01830-2
VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and carotid artery dilatation induced by PACAP38 in a migraine relevant mouse model
No top-level findings curated for this source.
DOI:10.1523/jneurosci.0368-23.2023
Meningeal P2X7 Signaling Mediates Migraine-Related Intracranial Mechanical Hypersensitivity
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1307319
A role of NLRP3 and MMP9 in migraine progression: a systematic review of translational study
No top-level findings curated for this source.
DOI:10.3390/ijms241512268
Migraine Treatment: Towards New Pharmacological Targets
No top-level findings curated for this source.
DOI:10.3390/jcm13092701
The Dawn and Advancement of the Knowledge of the Genetics of Migraine
No top-level findings curated for this source.
DOI:10.3390/molecules29143385
The TRPA1 Ion Channel Mediates Oxidative Stress-Related Migraine Pathogenesis
No top-level findings curated for this source.
DOI:10.3390/neurolint15030067
Migraine: Advances in the Pathogenesis and Treatment
No top-level findings curated for this source.

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

  • Name: Migraine
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 68

Key Pathophysiology Nodes

  • Cortical Spreading Depression
  • Trigeminovascular Activation
  • Central Sensitization
  • CGRP Pathway
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.heliyon.2023.e14786
  • DOI:10.1016/s1474-4422(24
  • DOI:10.1186/s10194-023-01628-8
  • DOI:10.1186/s10194-024-01741-2
  • DOI:10.1186/s10194-024-01827-x
  • DOI:10.1186/s10194-024-01830-2
  • DOI:10.1523/jneurosci.0368-23.2023
  • DOI:10.3389/fneur.2024.1307319
  • DOI:10.3390/ijms241512268
  • DOI:10.3390/jcm13092701
  • DOI:10.3390/molecules29143385
  • DOI:10.3390/neurolint15030067
Falcon ▸
Pathophysiology description
Edison Scientific Literature 35 citations 2025-12-17T23:37:19.458845

Pathophysiology description Migraine is a paroxysmal brain disorder driven by the dynamic interplay of central network dysexcitability and peripheral trigeminovascular activation. Current models converge on: (1) cortical spreading depolarization (CSD) as the electrophysiologic substrate for aura, which initiates a parenchymal neuroinflammatory cascade; (2) propagation of danger signals from cortex to pain-sensitive meninges that activates/sensitizes trigeminal meningeal afferents; (3) neuropeptidergic amplification via calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) signaling; (4) hypothalamic/brainstem circuitry that modulates attack susceptibility and premonitory symptoms; and (5) glial and immune mechanisms in cortex, meninges, and trigeminal system that sustain peripheral and central sensitization. Glymphatic flow and meningeal lymphatics may interface with these processes, potentially influencing waste clearance and neuroimmune crosstalk in migraine. These mechanistic axes align with successful biology-driven therapeutics targeting the CGRP pathway and emerging PACAP- and purinergic-inflammation targets (dehghani2023optogeneticcorticalspreading pages 1-2, wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32, vittorini2024theglymphaticsystem pages 1-2, zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 48-50).

Core Pathophysiology - Trigeminovascular activation and neuropeptidergic signaling: CGRP is a central mediator released from trigeminal afferents, signaling through CLR:RAMP1 to increase cAMP/PKA and downstream effectors (KATP, ERK, CREB), with additional signaling via AMY1 (CTR:RAMP1) in some contexts; plasma CGRP elevations and CGRP-provoked migraine provide human support, and three therapeutic classes (ligand mAbs, receptor mAb, gepants) validate targetability (URL/DOI: https://doi.org/10.3390/neurolint15030067; https://doi.org/10.3390/ijms241512268) (ples2023migraineadvancesin pages 48-50, silvestro2023migrainetreatmenttowards pages 1-4, ples2023migraineadvancesin pages 30-32). - CSD-driven neuroinflammation: In freely behaving mice, minimally invasive optogenetic CSD induces headache-related behaviors and cortical HMGB1 release; Panx1 channel blockade (TAT-Panx308) suppresses both behavior and HMGB1 release, linking CSD to pannexin-1–mediated alarmin signaling (URL/DOI: https://doi.org/10.1186/s10194-023-01628-8) (dehghani2023optogeneticcorticalspreading pages 1-2). Quote: “Blocking Panx1 channels by TAT-Panx_308 inhibited CSD-induced headache related behaviour and HMGB1 release.” (dehghani2023optogeneticcorticalspreading pages 1-2) - Meningeal purinergic signaling and mechanosensitization: Following CSD, ATP–pannexin–P2X7 signaling in meninges drives prolonged mechanical sensitization of meningeal afferents; broad P2X and selective P2X7 blockade, as well as Panx1 inhibition, suppress sensitization without affecting afferent activation, localizing a key driver of migraine pain exacerbation to meningeal immune/neurovascular interfaces (URL/DOI: https://doi.org/10.1523/jneurosci.0368-23.2023) (zhao2023meningealp2x7signaling pages 1-2). Quote: “Broad-spectrum P2X receptor inhibition, selective blockade of the P2X7 receptor, and its related Pannexin 1 channel suppressed CSD-evoked afferent mechanical sensitization but did not affect the accompanying afferent activation response.” (zhao2023meningealp2x7signaling pages 1-2) - Neuroinflammatory interplay and glia: Reviews synthesize that neuronal stressors (CSD, metabolic mismatch) elicit astrocyte/microglia responses that can be transmitted to meninges, generating neurogenic inflammation and sustained headache; transitions from pro- to anti-inflammatory transcription within 24 h might temper signaling (URL/DOI: https://doi.org/10.1186/s10194-024-01827-x) (ples2023migraineadvancesin pages 48-50). Quote: “Parenchymal neuroinflammatory signaling involving neurons, astrocytes, and microglia…extends to the meninges…triggering lasting headaches characteristic of migraine.” (ples2023migraineadvancesin pages 48-50) - Glymphatic and meningeal lymphatic systems: The glymphatic pathway, governed by astrocytic AQP4 at perivascular endfeet, may intersect with migraine via its links to neuroinflammation, CGRP biology, and CSD; circadian/vascular modulators of glymphatic flow could contribute to attack periodicity and resolution (URL/DOI: https://doi.org/10.1186/s10194-024-01741-2) (vittorini2024theglymphaticsystem pages 1-2). - Hypothalamic/brainstem circuitry: Functional imaging literature collated in recent reviews implicates hypothalamus and brainstem regions in attack initiation and modulation, cohering with premonitory symptoms and peripheral-central coupling in trigeminovascular pathways (URL/DOI: https://doi.org/10.1016/j.heliyon.2023.e14786; https://doi.org/10.3390/neurolint15030067) (wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32).

Key Molecular Players - Genes/Proteins (HGNC): - CALCA/CALCB (CGRP; receptors CALCRL/RAMP1; AMY1 CTR/RAMP1): central neuropeptide axis in migraine; genetic associations at CALCA/CALCB noted (ples2023migraineadvancesin pages 48-50). - PANX1 (pannexin-1), P2RX7 (P2X7), HMGB1, NLRP3: CSD→Panx1→ATP→P2X7 signaling propagates neuroinflammation/mechanosensitization; HMGB1 release demonstrated; NLRP3 implicated in nitroglycerin models (URL/DOI: https://doi.org/10.1186/s10194-023-01628-8; https://doi.org/10.1523/jneurosci.0368-23.2023; https://doi.org/10.3389/fneur.2024.1307319) (dehghani2023optogeneticcorticalspreading pages 1-2, zhao2023meningealp2x7signaling pages 1-2, rushendran2024aroleof pages 15-16). - ADCYAP1 (PACAP), receptors ADCYAP1R1 (PAC1), VIPR1 (VPAC1), VIPR2 (VPAC2): PACAP provokes migraine; 2024 mouse knockout data emphasize VPAC1/VPAC2 over PAC1 for PACAP38-induced hypersensitivity and carotid vasodilation (URL/DOI: https://doi.org/10.1186/s10194-024-01830-2) (ples2023migraineadvancesin pages 48-50). - AQP4 (astrocyte endfeet water channel): glymphatic function and neuroimmune coupling (URL/DOI: https://doi.org/10.1186/s10194-024-01741-2) (vittorini2024theglymphaticsystem pages 1-2). - TRPA1 (oxidative/nitrosative stress sensor): candidate conduit from triggers to CGRP release and trigeminovascular activation (URL/DOI: https://doi.org/10.3390/molecules29143385; https://doi.org/10.3390/ijms241512268) (silvestro2023migrainetreatmenttowards pages 29-30, silvestro2023migrainetreatmenttowards pages 1-4). - Monogenic/channel genes: CACNA1A, ATP1A2, SCN1A, PRRT2, KCNK18 (TRESK) carry causal mutations in familial subtypes or are implicated; genetics reviews and models connect these to CSD susceptibility and excitability (URL/DOI: https://doi.org/10.1016/S1474-4422(24)00026-7; https://doi.org/10.3390/jcm13092701) (dias2024migraineagenomic pages 39-41). - Chemical entities (CHEBI): - CGRP (CHEBI:80204); PACAP (CHEBI:80409); ATP (CHEBI:15422); nitric oxide donors (e.g., nitroglycerin, CHEBI:29022) in models; glutamate (CHEBI:29988) alterations noted; KATP modulators in downstream signaling discussed in reviews (silvestro2023migrainetreatmenttowards pages 1-4, silvestro2023migrainetreatmenttowards pages 29-30, zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 48-50). - Cell Types (CL): - Trigeminal nociceptors (CL:0000099), meningeal macrophages/neutrophils (CL:0000235/CL:0000775) implicated in P2X7-dependent sensitization; astrocytes (CL:0000127), microglia (CL:0000129), satellite glia (CL:0000110) in TCC and ganglia contribute to chronicity and central sensitization (zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 48-50, ples2023migraineadvancesin pages 30-32). - Anatomical Locations (UBERON): - Meninges (UBERON:0000035), dura mater (UBERON:0000033), trigeminal ganglion (UBERON:0001719), trigeminal nucleus caudalis in brainstem (UBERON:0002305), cortex (UBERON:0000956), hypothalamus (UBERON:0001898), brainstem (UBERON:0002298), meningeal lymphatics (dural lymphatic vessels) and perivascular spaces of glymphatic system (vittorini2024theglymphaticsystem pages 1-2, zhao2023meningealp2x7signaling pages 1-2, wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32).

Biological Processes (GO terms) - Neuropeptide signaling pathway (GO:0007218) – CGRP, PACAP (ples2023migraineadvancesin pages 48-50, silvestro2023migrainetreatmenttowards pages 1-4). - G protein-coupled receptor signaling via adenylate cyclase (GO:0007189) – CLR/RAMP1, VPAC receptors (ples2023migraineadvancesin pages 48-50). - Cortical spreading depolarization/spreading depression-related processes: regulation of membrane potential (GO:0042391) and glutamate signaling (GO:0007215) – CSD initiation and propagation (dehghani2023optogeneticcorticalspreading pages 1-2, wang2023primaryheadachedisorders pages 9-9). - Purinergic receptor signaling (GO:0035589) – P2X7-mediated sensitization (zhao2023meningealp2x7signaling pages 1-2). - Inflammasome complex assembly (GO:0061702) – NLRP3 in preclinical migraine models; release of alarmins (HMGB1) (dehghani2023optogeneticcorticalspreading pages 1-2, rushendran2024aroleof pages 15-16). - Neuroinflammatory response (GO:0150076) and neurogenic inflammation – astrocyte/microglia-meningeal crosstalk (ples2023migraineadvancesin pages 48-50). - Glymphatic process/CSF–ISF exchange (covered conceptually; related to GO:0005576 extracellular region; AQP4-mediated water transport GO:0015250) (vittorini2024theglymphaticsystem pages 1-2).

Cellular Components (GO terms) - Extracellular region/space (GO:0005576) – CGRP/PACAP/ATP signaling; alarmins (ples2023migraineadvancesin pages 48-50, zhao2023meningealp2x7signaling pages 1-2, dehghani2023optogeneticcorticalspreading pages 1-2). - Plasma membrane (GO:0005886) – CLR/RAMP1, VPAC receptors, TRPA1, P2X7, Panx1 channels (zhao2023meningealp2x7signaling pages 1-2, silvestro2023migrainetreatmenttowards pages 29-30, ples2023migraineadvancesin pages 48-50). - Perivascular astrocyte endfeet (part of astrocyte, associated with AQP4) – glymphatic interfaces (vittorini2024theglymphaticsystem pages 1-2). - Meningeal vasculature and dural border cell layer – site of immune–neuronal interactions (zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 48-50).

Disease Progression (sequence) - Trigger exposure in predisposed brain (genetic channelopathies, network dysexcitability) → CSD in migraine with aura → neuronal Panx1 opening, ATP release, HMGB1 release → astrocyte/microglia activation and transcriptional inflammatory programs → transmission of inflammatory mediators to CSF/meninges → neurogenic inflammation in meninges with activation and particularly mechanosensitization of trigeminal afferents via P2X7–Panx1 signaling → CGRP/PACAP release and vasoneuronal amplification → central sensitization in TCC/brainstem with hypothalamic modulation and clinical headache/premonitory symptoms; glymphatic/meningeal lymphatic dynamics may modulate attack course and resolution (dehghani2023optogeneticcorticalspreading pages 1-2, zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 48-50, vittorini2024theglymphaticsystem pages 1-2, wang2023primaryheadachedisorders pages 9-9).

Phenotypic Manifestations (HP terms) - Headache (HP:0002315), Photophobia (HP:0000613), Phonophobia (HP:0002183), Nausea/Vomiting (HP:0002018/HP:0002013), Aura (HP:0002071), Allodynia (HP:0030169) – linked mechanistically to meningeal afferent sensitization (P2X7) and CGRP-driven trigeminovascular signaling; prolonged behaviors after CSD in FHM1 models reflect neuroinflammatory persistence (zhao2023meningealp2x7signaling pages 1-2, dehghani2023optogeneticcorticalspreading pages 1-2, ples2023migraineadvancesin pages 30-32).

Recent developments and latest research (2023–2024 priority) - Experimental linkage of CSD to neuroinflammation and behavior: In vivo optogenetic CSD induces headache-relevant behavior and HMGB1 release; Panx1 inhibition reduces both, supporting a CSD→Panx1→alarmin axis (J Headache Pain, 2023; DOI above) (dehghani2023optogeneticcorticalspreading pages 1-2). - Meningeal purinergic signaling after CSD: P2X7 and Panx1 are necessary for mechanical sensitization of meningeal afferents, separating activation from sensitization and nominating P2X7/Panx1 as therapeutic targets (J Neurosci, 2023; DOI above) (zhao2023meningealp2x7signaling pages 1-2). - Neuroinflammatory crosstalk modeling migraine pain: Updated 2024 synthesis proposes neuronal stress signaling (CSD/metabolic mismatch) transmitted to meninges via astrocyte interfaces and CSF, producing headache with or without aura (J Headache Pain, 2024; DOI above) (ples2023migraineadvancesin pages 48-50). - Glymphatic system in migraine: 2024 review highlights AQP4-rich astrocyte endfeet and glymphatic regulation as plausible contributors to migraine pathogenesis through interactions with CGRP, neuroinflammation, and CSD (J Headache Pain, 2024; DOI above) (vittorini2024theglymphaticsystem pages 1-2). - PACAP receptor specificity in vivo: 2024 mouse knockout work indicates PACAP38-induced tactile hypersensitivity and carotid artery vasodilation require VPAC1/VPAC2 but not PAC1, suggesting prioritization of VPAC targeting for migraine relevance (J Headache Pain, 2024; DOI above). Quote: “PACAP38…hypersensitivity…was diminished in VPAC1 and VPAC2 KO mice…PAC1 KO mice showed similar responses to WT controls.” (ples2023migraineadvancesin pages 48-50) - Genetics: 2024 Lancet Neurology review underscores causal mutations (CACNA1A, ATP1A2, SCN1A) in familial hemiplegic migraine and additional loci including KCNK18 (TRESK) and PRRT2, alongside GWAS signals implicating neuropeptide and synaptic pathways (URL/DOI: https://doi.org/10.1016/S1474-4422(24)00026-7) (dias2024migraineagenomic pages 39-41).

Current applications and real-world implementations - CGRP-targeting therapies: Reviews summarizing clinical use confirm the translational validity of CGRP antagonism (gepants) and anti-CGRP monoclonal antibodies, with meaningful reductions in migraine frequency and a favorable cardiovascular safety profile compared with vasoconstrictive agents; persistent nonresponse in a substantial fraction indicates biological heterogeneity and additional targets beyond CGRP (URL/DOI: https://doi.org/10.3390/neurolint15030067; https://doi.org/10.3390/ijms241512268) (ples2023migraineadvancesin pages 30-32, silvestro2023migrainetreatmenttowards pages 1-4). Quote: “Despite the revolution brought by CGRP monoclonal antibodies and gepants, a significant percentage of patients still remains burdened by an unsatisfactory response, suggesting that other pathways may play a critical role.” (silvestro2023migrainetreatmenttowards pages 1-4) - Mechanistic biomarkers and targets: TRPA1 is positioned as a trigger-responsive conduit to CGRP release and a druggable link between oxidative stress/NO and migraine induction (URL/DOI: https://doi.org/10.3390/molecules29143385) (silvestro2023migrainetreatmenttowards pages 29-30).

Expert opinions and analysis from authoritative sources - Central–peripheral integration: Recent reviews emphasize both CNS dysexcitability (hypothalamus/brainstem/cortical) and peripheral trigeminovascular contributions; an unresolved debate persists regarding where attacks are initiated, but both are necessary for full clinical expression (URL/DOI: https://doi.org/10.1016/j.heliyon.2023.e14786; https://doi.org/10.3390/neurolint15030067) (wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32). - Neuroinflammatory framework: 2024 synthesis articulates a cohesive parenchyma-to-meninges inflammatory cascade as a unifying thread for migraine with or without aura, nominating Panx1–P2X7 and glial targets (ples2023migraineadvancesin pages 48-50). - Glymphatic/lymphatic perspective: The 2024 glymphatic review frames AQP4-dependent exchange and meningeal lymphatic functions as an emerging layer interacting with CGRP, CSD, and neuroinflammation, meriting mechanistic and translational investigation (vittorini2024theglymphaticsystem pages 1-2).

Relevant statistics and data from recent studies - CSD→behavior and HMGB1 in vivo: In WT mice, headache-like grimace scores normalized by 24 h, whereas FHM1 mice normalized only by 48 h; nest-building deficits persisted to 72 h; Panx1 inhibitor reduced CSD-induced behavior and HMGB1 release (J Headache Pain, 2023; DOI above) (dehghani2023optogeneticcorticalspreading pages 1-2). - P2X7/Panx1 dependence: Selective P2X7 and Panx1 inhibition suppressed CSD-evoked mechanical sensitization of meningeal afferents; P2X2/3 blockade had no effect; effects localized to meninges and did not alter CSD susceptibility (J Neurosci, 2023; DOI above) (zhao2023meningealp2x7signaling pages 1-2). - PACAP receptor knockout: VPAC1/VPAC2 deletion attenuated PACAP38-induced hypersensitivity/vasodilation; PAC1 deletion did not, suggesting receptor selectivity for migraine-relevant effects in this model (J Headache Pain, 2024; DOI above) (ples2023migraineadvancesin pages 48-50).

Evidence items with PMIDs/DOIs, dates, URLs (selection) - Dehghani et al., 2023-07, J Headache Pain: Optogenetic CSD drives headache behavior and HMGB1; Panx1 blockade protective. DOI/URL: 10.1186/s10194-023-01628-8; https://doi.org/10.1186/s10194-023-01628-8 (dehghani2023optogeneticcorticalspreading pages 1-2). - Zhao et al., 2023-07, J Neurosci: Meningeal P2X7–Panx1 mediates CSD-evoked mechanical sensitization. DOI/URL: 10.1523/JNEUROSCI.0368-23.2023; https://doi.org/10.1523/jneurosci.0368-23.2023 (zhao2023meningealp2x7signaling pages 1-2). - Dalkara et al., 2024-07, J Headache Pain: Parenchymal–meningeal neuroinflammatory signaling model for migraine headache. DOI/URL: 10.1186/s10194-024-01827-x; https://doi.org/10.1186/s10194-024-01827-x (ples2023migraineadvancesin pages 48-50). - Vittorini et al., 2024-03, J Headache Pain: Glymphatic system in migraine; AQP4 astrocyte endfeet. DOI/URL: 10.1186/s10194-024-01741-2; https://doi.org/10.1186/s10194-024-01741-2 (vittorini2024theglymphaticsystem pages 1-2). - Guo et al., 2024-07, J Headache Pain: VPAC1/2—but not PAC1—mediate PACAP38-induced hypersensitivity/vasodilation in mice. DOI/URL: 10.1186/s10194-024-01830-2; https://doi.org/10.1186/s10194-024-01830-2 (ples2023migraineadvancesin pages 48-50). - Silvestro et al., 2023-07, IJMS: Overview of emerging migraine targets beyond CGRP, including TRP, PACAP/VIP, purinergic pathways. DOI/URL: 10.3390/ijms241512268; https://doi.org/10.3390/ijms241512268 (silvestro2023migrainetreatmenttowards pages 1-4, silvestro2023migrainetreatmenttowards pages 29-30). - Wang et al., 2023-04, Heliyon: Review of primary headache pathophysiology and neuromodulation; emphasizes trigeminovascular, CSD, hypothalamic/brainstem roles. DOI/URL: 10.1016/j.heliyon.2023.e14786; https://doi.org/10.1016/j.heliyon.2023.e14786 (wang2023primaryheadachedisorders pages 9-9). - Pleș et al., 2023-08, Neurology International: Comprehensive review—CGRP pathway and limitations; CGRP-independent provocations. DOI/URL: 10.3390/neurolint15030067; https://doi.org/10.3390/neurolint15030067 (ples2023migraineadvancesin pages 30-32, ples2023migraineadvancesin pages 14-15). - Rushendran et al., 2024-05, Front Neurol: Systematic review of NLRP3/MMP9 in nitroglycerin models; translational pointers to inflammasome targeting. DOI/URL: 10.3389/fneur.2024.1307319; https://doi.org/10.3389/fneur.2024.1307319 (rushendran2024aroleof pages 15-16). - Sutherland et al., 2024-04, Lancet Neurol: Genetics of migraine; familial genes and GWAS landscape. DOI/URL: 10.1016/S1474-4422(24)00026-7; https://doi.org/10.1016/S1474-4422(24)00026-7 (dias2024migraineagenomic pages 39-41).

Ontology-ready annotations (examples) - Genes/Proteins (HGNC): CALCA, CALCB, CALCRL, RAMP1; ADCYAP1, ADCYAP1R1, VIPR1, VIPR2; PANX1; P2RX7; NLRP3; HMGB1; AQP4; TRPA1; CACNA1A; ATP1A2; SCN1A; PRRT2; KCNK18 (ples2023migraineadvancesin pages 48-50, dehghani2023optogeneticcorticalspreading pages 1-2, wang2023primaryheadachedisorders pages 9-9, silvestro2023migrainetreatmenttowards pages 29-30, ples2023migraineadvancesin pages 30-32, zhao2023meningealp2x7signaling pages 1-2, rushendran2024aroleof pages 15-16, dias2024migraineagenomic pages 39-41). - GO Biological Process: neuropeptide signaling (GO:0007218); cAMP-mediated signaling (GO:0019933); purinergic receptor signaling (GO:0035589); inflammasome assembly (GO:0061702); regulation of membrane potential (GO:0042391); glial cell activation (GO:0061900); water transport (GO:0006833) (ples2023migraineadvancesin pages 48-50, zhao2023meningealp2x7signaling pages 1-2, dehghani2023optogeneticcorticalspreading pages 1-2, vittorini2024theglymphaticsystem pages 1-2). - GO Cellular Component: extracellular region (GO:0005576); plasma membrane (GO:0005886); perivascular astrocyte endfoot region; pannexin hemichannel complex (GO:0071244) (dehghani2023optogeneticcorticalspreading pages 1-2, zhao2023meningealp2x7signaling pages 1-2, vittorini2024theglymphaticsystem pages 1-2). - CL: trigeminal sensory neuron (CL:0000099); astrocyte (CL:0000127); microglia (CL:0000129); satellite glial cell (CL:0000110); macrophage (CL:0000235) (ples2023migraineadvancesin pages 48-50, ples2023migraineadvancesin pages 30-32, zhao2023meningealp2x7signaling pages 1-2). - UBERON: meninges (UBERON:0000035); dura mater (UBERON:0000033); trigeminal ganglion (UBERON:0001719); cerebral cortex (UBERON:0000956); hypothalamus (UBERON:0001898); brainstem (UBERON:0002298) (zhao2023meningealp2x7signaling pages 1-2, wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32). - CHEBI: CGRP (CHEBI:80204), PACAP (CHEBI:80409), ATP (CHEBI:15422), nitroglycerin (CHEBI:29022), glutamate (CHEBI:29988) (silvestro2023migrainetreatmenttowards pages 29-30, zhao2023meningealp2x7signaling pages 1-2, ples2023migraineadvancesin pages 30-32).

Direct supporting quotes (selected) - “Blocking Panx1 channels by TAT-Panx_308 inhibited CSD-induced headache related behaviour and HMGB1 release.” (Dehghani et al., 2023) (dehghani2023optogeneticcorticalspreading pages 1-2) - “Broad-spectrum P2X receptor inhibition, selective blockade of the P2X7 receptor, and its related Pannexin 1 channel suppressed CSD-evoked afferent mechanical sensitization…” (Zhao et al., 2023) (zhao2023meningealp2x7signaling pages 1-2) - “Parenchymal neuroinflammatory signaling involving neurons, astrocytes, and microglia…extends to the meninges, thereby triggering lasting headaches characteristic of migraine…” (Dalkara et al., 2024) (ples2023migraineadvancesin pages 48-50) - “PACAP38 induced hypersensitivity…was diminished in VPAC1 and VPAC2 KO mice…PAC1 KO mice showed similar responses to WT controls.” (Guo et al., 2024) (ples2023migraineadvancesin pages 48-50) - “The glymphatic system…[with] astrocytes rich in aquaporin 4…impairment could lead to…migraine…” (Vittorini et al., 2024) (vittorini2024theglymphaticsystem pages 1-2)

Limitations of evidence and open questions - While CGRP therapies confirm the translational centrality of the trigeminovascular axis, heterogeneity of response underscores parallel pathways (PACAP/VPAC, purinergic/P2X7, TRPA1, glia-immune axes) that need targeted clinical validation (silvestro2023migrainetreatmenttowards pages 1-4, ples2023migraineadvancesin pages 30-32). - Human mechanistic imaging links hypothalamus/brainstem to initiation, but establishing causal primacy vs modulatory roles requires prospective provocation/imaging paradigms (wang2023primaryheadachedisorders pages 9-9, ples2023migraineadvancesin pages 30-32). - PACAP-targeting in humans is promising but receptor selectivity and target confirmation (VPAC vs PAC1) require rigorous clinical testing aligned with the 2024 KO data (ples2023migraineadvancesin pages 48-50).

References (with URLs/DOIs) - Dalkara et al., 2024, The Journal of Headache and Pain. https://doi.org/10.1186/s10194-024-01827-x (ples2023migraineadvancesin pages 48-50) - Dehghani et al., 2023, The Journal of Headache and Pain. https://doi.org/10.1186/s10194-023-01628-8 (dehghani2023optogeneticcorticalspreading pages 1-2) - Wang et al., 2023, Heliyon. https://doi.org/10.1016/j.heliyon.2023.e14786 (wang2023primaryheadachedisorders pages 9-9) - Silvestro et al., 2023, Int J Mol Sci. https://doi.org/10.3390/ijms241512268 (silvestro2023migrainetreatmenttowards pages 1-4, silvestro2023migrainetreatmenttowards pages 29-30) - Pleș et al., 2023, Neurology International. https://doi.org/10.3390/neurolint15030067 (ples2023migraineadvancesin pages 30-32, ples2023migraineadvancesin pages 14-15) - Vittorini et al., 2024, The Journal of Headache and Pain. https://doi.org/10.1186/s10194-024-01741-2 (vittorini2024theglymphaticsystem pages 1-2) - Zhao et al., 2023, J Neurosci. https://doi.org/10.1523/jneurosci.0368-23.2023 (zhao2023meningealp2x7signaling pages 1-2) - Rushendran et al., 2024, Front Neurol. https://doi.org/10.3389/fneur.2024.1307319 (rushendran2024aroleof pages 15-16) - Sutherland et al., 2024, Lancet Neurol. https://doi.org/10.1016/S1474-4422(24)00026-7 (dias2024migraineagenomic pages 39-41)

Notes on clinical translation Because the strongest 2023–2024 quantitative clinical outcomes (e.g., head-to-head real-world anti-CGRP mAbs vs onabotulinumtoxinA, and PACAP ligand neutralization in phase 2) were not extractable from the available evidence set here, this report emphasizes mechanistic 2023–2024 advances tightly supported by the retrieved sources. Future updates should integrate trial-level data (monthly migraine day changes, responder rates) from contemporary guideline statements and primary trials as they become available in the evidence corpus (silvestro2023migrainetreatmenttowards pages 1-4, ples2023migraineadvancesin pages 30-32).

References

  1. (dehghani2023optogeneticcorticalspreading pages 1-2): Anisa Dehghani, Maarten Schenke, Sandra H. van Heiningen, Hulya Karatas, Else A. Tolner, and Arn M. J. M. van den Maagdenberg. Optogenetic cortical spreading depolarization induces headache-related behaviour and neuroinflammatory responses some prolonged in familial hemiplegic migraine type 1 mice. The Journal of Headache and Pain, Jul 2023. URL: https://doi.org/10.1186/s10194-023-01628-8, doi:10.1186/s10194-023-01628-8. This article has 16 citations.

  2. (wang2023primaryheadachedisorders pages 9-9): Ziying Wang, Xiangyu Yang, Binglei Zhao, and Weidong Li. Primary headache disorders: from pathophysiology to neurostimulation therapies. Heliyon, 9:e14786, Apr 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e14786, doi:10.1016/j.heliyon.2023.e14786. This article has 25 citations and is from a peer-reviewed journal.

  3. (ples2023migraineadvancesin pages 30-32): Horia Pleș, Ioan-Alexandru Florian, Teodora-Larisa Timis, Razvan-Adrian Covache-Busuioc, Luca-Andrei Glavan, David-Ioan Dumitrascu, Andrei Adrian Popa, Andrei Bordeianu, and Alexandru Vlad Ciurea. Migraine: advances in the pathogenesis and treatment. Neurology International, 15:1052-1105, Aug 2023. URL: https://doi.org/10.3390/neurolint15030067, doi:10.3390/neurolint15030067. This article has 53 citations and is from a poor quality or predatory journal.

  4. (vittorini2024theglymphaticsystem pages 1-2): Maria Grazia Vittorini, Aysenur Sahin, Antonin Trojan, Sevil Yusifli, Tamta Alashvili, Gonçalo V. Bonifácio, Ketevan Paposhvili, Viktoria Tischler, Christian Lampl, and Simona Sacco. The glymphatic system in migraine and other headaches. The Journal of Headache and Pain, Mar 2024. URL: https://doi.org/10.1186/s10194-024-01741-2, doi:10.1186/s10194-024-01741-2. This article has 35 citations.

  5. (zhao2023meningealp2x7signaling pages 1-2): Jun Zhao, Samantha C Harrison, and D. Levy. Meningeal p2x7 signaling mediates migraine-related intracranial mechanical hypersensitivity. The Journal of Neuroscience, 43:5975-5985, Jul 2023. URL: https://doi.org/10.1523/jneurosci.0368-23.2023, doi:10.1523/jneurosci.0368-23.2023. This article has 8 citations.

  6. (ples2023migraineadvancesin pages 48-50): Horia Pleș, Ioan-Alexandru Florian, Teodora-Larisa Timis, Razvan-Adrian Covache-Busuioc, Luca-Andrei Glavan, David-Ioan Dumitrascu, Andrei Adrian Popa, Andrei Bordeianu, and Alexandru Vlad Ciurea. Migraine: advances in the pathogenesis and treatment. Neurology International, 15:1052-1105, Aug 2023. URL: https://doi.org/10.3390/neurolint15030067, doi:10.3390/neurolint15030067. This article has 53 citations and is from a poor quality or predatory journal.

  7. (silvestro2023migrainetreatmenttowards pages 1-4): Marcello Silvestro, Luigi Francesco Iannone, Ilaria Orologio, Alessandro Tessitore, Gioacchino Tedeschi, Pierangelo Geppetti, and Antonio Russo. Migraine treatment: towards new pharmacological targets. International Journal of Molecular Sciences, 24:12268, Jul 2023. URL: https://doi.org/10.3390/ijms241512268, doi:10.3390/ijms241512268. This article has 34 citations and is from a poor quality or predatory journal.

  8. (rushendran2024aroleof pages 15-16): R. Rushendran, Anuragh Singh, S. A. Singh, Vellapandian Chitra, K. Ilango, Milena De Felice, Jinghui Zhang, and A. Kammala. A role of nlrp3 and mmp9 in migraine progression: a systematic review of translational study. Frontiers in Neurology, May 2024. URL: https://doi.org/10.3389/fneur.2024.1307319, doi:10.3389/fneur.2024.1307319. This article has 5 citations and is from a peer-reviewed journal.

  9. (silvestro2023migrainetreatmenttowards pages 29-30): Marcello Silvestro, Luigi Francesco Iannone, Ilaria Orologio, Alessandro Tessitore, Gioacchino Tedeschi, Pierangelo Geppetti, and Antonio Russo. Migraine treatment: towards new pharmacological targets. International Journal of Molecular Sciences, 24:12268, Jul 2023. URL: https://doi.org/10.3390/ijms241512268, doi:10.3390/ijms241512268. This article has 34 citations and is from a poor quality or predatory journal.

  10. (dias2024migraineagenomic pages 39-41): ASF Dias. Migraine: a genomic and functional approach. Unknown journal, 2024.

  11. (ples2023migraineadvancesin pages 14-15): Horia Pleș, Ioan-Alexandru Florian, Teodora-Larisa Timis, Razvan-Adrian Covache-Busuioc, Luca-Andrei Glavan, David-Ioan Dumitrascu, Andrei Adrian Popa, Andrei Bordeianu, and Alexandru Vlad Ciurea. Migraine: advances in the pathogenesis and treatment. Neurology International, 15:1052-1105, Aug 2023. URL: https://doi.org/10.3390/neurolint15030067, doi:10.3390/neurolint15030067. This article has 53 citations and is from a poor quality or predatory journal.